ECG Effects of Dofetilide, Moxifloxacin, Dofetilide+Mexiletine, Dofetilide+Lidocaine and Moxifloxacin+Diltiazem 1.0.0
(1,042,882 bytes)
EGREFID | RANDID | SEX | AGE | HGHT | WGHT | SYSBP | DIABP | RACE | ETHNIC | ARMCD | VISIT | TRTA | DOF | LIDO | MEXI | MOXI | MOXI.M2 | DILT | TPT | BASELINE | RR | PR | QT | QRS | JTPEAK | TPEAKTEND | TPEAKTPEAKP | ERD_30 | LRD_30 | Twave_amplitude | Twave_asymmetry | Twave_flatness |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39BF8219-C83A-4121-926F-2BC730FBE127 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1124 | 166 | 420 | 72 | 263 | 85 | NA | 52 | 28 | 727.7845179035 | 0.1929824501 | 0.5300399661 |
905B0D27-D4E7-4812-8895-48E2B58B6757 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1150 | 173 | 420 | 75 | 261 | 84 | NA | 50 | 29 | 733.9128652054 | 0.2037037015 | 0.5382068753 |
EB1CD234-82BC-4AD4-A7A8-15EC0FFFA6BF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1134 | 169 | 421 | 74 | 260 | 87 | NA | 54 | 30 | 699.2899747933 | 0.2363636345 | 0.5367771983 |
46869F3C-5097-412B-9B99-30E3FB4670C5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 1063 | 168 | 398 | 76 | 234 | 88 | NA | 55 | 30 | 612.590936922 | 0.2321428508 | 0.5149975419 |
6092BAC1-5069-4937-B7E5-3EED96308E2C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 1018 | 168 | 397 | 74 | 236 | 87 | NA | 65 | 36 | 576.7663206689 | 0.2962962985 | 0.5162849426 |
F1ACF2BB-C68A-4026-B3D8-0CFFED9D29FB | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 1044 | 166 | 398 | 76 | 234 | 88 | NA | 63 | 37 | 576.7774771523 | 0.2363636345 | 0.5098620653 |
234B7892-E996-4CCD-A4B5-C6D1E67A4C4E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 1017 | 168 | 390 | 69 | 235 | 86 | NA | 52 | 33 | 626.6630259438 | 0.2321428508 | 0.4949404895 |
559E8009-F4A8-4495-A1E5-951AFC04D957 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 988 | 167 | 389 | 70 | 235 | 84 | NA | 52 | 28 | 656.7525929846 | 0.2800000012 | 0.4923144579 |
65986F03-9A19-4FAF-BF3B-0C7A64236DF1 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 1122 | 171 | 391 | 77 | 229 | 85 | NA | 52 | 30 | 653.7431401684 | 0.2307692319 | 0.4943392873 |
C188D335-151F-453C-B1D2-A207A9B6B894 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 1098 | 170 | 393 | 67 | 243 | 83 | NA | 51 | 30 | 680.6025244861 | 0.2222222239 | 0.5019184351 |
CBC5F7F0-2AF3-44CD-9854-208048B9C621 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 1059 | 170 | 393 | 68 | 241 | 84 | NA | 51 | 28 | 677.4705926778 | 0.2452830225 | 0.5013114214 |
F560D070-1A7B-4CC5-B92A-D86FF54BA927 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 1052 | 168 | 393 | 68 | 241 | 84 | NA | 50 | 28 | 707.9294971651 | 0.2075471729 | 0.4958449602 |
480D519A-756A-4A1F-AEE1-4C7BCA4C663B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 1107 | 164 | 390 | 65 | 242 | 83 | NA | 48 | 26 | 839.0385648623 | 0.1923076957 | 0.4900842309 |
DA775214-A3D7-4221-B76E-49D8CCF93E8B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 1096 | 162 | 389 | 66 | 239 | 84 | NA | 48 | 28 | 809.2042050135 | 0.1960784346 | 0.4899588525 |
EEE37BE1-B0AC-4BAA-8BD9-A5B474D2FC4E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 1099 | 164 | 388 | 66 | 239 | 83 | NA | 47 | 28 | 840.5167140785 | 0.1960784346 | 0.4855643809 |
54CF5774-3205-4FBE-B018-C94581CD204B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 989 | 159 | 390 | 69 | 229 | 92 | NA | 65 | 41 | 550.1821113835 | 0.2456140369 | 0.4902038276 |
D6652388-CCC2-43D3-8D94-FD3408B14E61 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 1015 | 161 | 390 | 71 | 229 | 90 | NA | 64 | 41 | 565.4771710434 | 0.2068965584 | 0.499338299 |
DF0BF6D6-B1C5-4984-BD8E-FEBF8DBA975F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 988 | 158 | 390 | 71 | 229 | 90 | NA | 63 | 39 | 568.4239573448 | 0.2321428508 | 0.4896709025 |
112D3767-4F93-4245-B31D-30505B7E8FCF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 1004 | 161 | 392 | 70 | 235 | 87 | NA | 56 | 35 | 559.2555138794 | 0.25 | 0.5023309588 |
6497AA8A-6FE0-44EE-8963-48AFC8FB3AD4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 1053 | 163 | 392 | 69 | 232 | 91 | NA | 58 | 37 | 532.8455206688 | 0.2456140369 | 0.4991591275 |
914CF47E-EB90-4E95-AFA3-FA77CED1CB14 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 987 | 166 | 393 | 69 | 233 | 91 | NA | 57 | 35 | 550.0464740896 | 0.2592592537 | 0.4997153878 |
61E62526-91F0-47E4-A3C9-11AFAAF27AE6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 980 | 161 | 390 | 70 | 233 | 87 | NA | 55 | 34 | 565.4491649393 | 0.2321428508 | 0.5002769828 |
6C52824B-A5FE-4C74-AEEC-E2621A6A58FD | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 1031 | 162 | 395 | 70 | 237 | 88 | NA | 54 | 33 | 577.1156608148 | 0.2068965584 | 0.501023531 |
BC3A08DE-FF17-4C11-B285-76A36D212530 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 1010 | 165 | 390 | 70 | 234 | 86 | NA | 54 | 33 | 596.5643262137 | 0.2456140369 | 0.5019412637 |
9DBB43F0-6016-4153-8CD6-A675C147DEDC | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 1021 | 161 | 387 | 71 | 230 | 86 | NA | 53 | 30 | 678.5828227941 | 0.200000003 | 0.4916217625 |
C572DBF0-28F2-41DA-A1A1-0D35065F38D9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 999 | 162 | 388 | 71 | 230 | 87 | NA | 59 | 38 | 639.6676052192 | 0.2037037015 | 0.4888770282 |
D3F83CAF-FCF0-415B-90D2-41C2ABF68232 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 1040 | 163 | 390 | 72 | 231 | 87 | NA | 52 | 34 | 643.9732191903 | 0.1785714328 | 0.488887459 |
08D58E4C-2910-45B6-B83A-DC4BD6DC987C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 950 | 161 | 388 | 69 | 231 | 88 | NA | 60 | 38 | 643.740985995 | 0.2884615362 | 0.4883843958 |
9221F9F4-B330-4476-97E8-FAF6B859C70C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 957 | 163 | 387 | 69 | 233 | 85 | NA | 61 | 33 | 660.5506025851 | 0.269230783 | 0.4905666709 |
DE6B0375-C2D9-4197-A08B-24EB2EB67946 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 966 | 161 | 388 | 68 | 234 | 86 | NA | 60 | 37 | 641.1557961952 | 0.2909090817 | 0.4859688282 |
07AD6C75-E4B7-4F6B-B264-F9FA5DB4F8B7 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 1014 | 164 | 400 | 71 | 241 | 88 | NA | 54 | 30 | 677.4754002715 | 0.2830188572 | 0.5121054053 |
38BA92FE-B1FC-4FFA-BA09-A02EFDE08583 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 1058 | 166 | 406 | 69 | 244 | 93 | NA | 56 | 32 | 646.0555877907 | 0.2909090817 | 0.5242316127 |
850D5757-E1FE-48F3-B6C1-071F44DB4591 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 997 | 161 | 406 | 68 | 243 | 95 | NA | 72 | 40 | 564.447384074 | 0.4363636374 | 0.5274394751 |
7BA1168C-7E82-4CD1-81CB-681AC872C7F3 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 1024 | 164 | 397 | 69 | 238 | 90 | NA | 54 | 33 | 619.6665229896 | 0.301886797 | 0.5068323016 |
BCE77330-7743-4085-8559-37643E933732 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 1011 | 164 | 393 | 69 | 234 | 90 | NA | 53 | 33 | 631.9404364453 | 0.2641509473 | 0.5001778007 |
CDA2E533-2356-4E2D-A3D3-6AB8C675F1DD | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 1015 | 163 | 397 | 69 | 239 | 89 | NA | 56 | 33 | 613.1436774966 | 0.3090909123 | 0.5065523982 |
6C8F2C47-0515-42AD-9380-0B4D671DA46B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 957 | 164 | 387 | 69 | 228 | 90 | NA | 61 | 36 | 636.5503785852 | 0.2407407463 | 0.4889936745 |
E4132895-C759-46E7-8548-45AFC15F6DA8 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 962 | 160 | 387 | 70 | 230 | 87 | NA | 61 | 34 | 644.6263062272 | 0.2830188572 | 0.4910051823 |
E78631D3-3FBF-4BEB-891E-9AFE63BDF4C7 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 979 | 159 | 387 | 71 | 227 | 89 | NA | 61 | 37 | 628.7288955112 | 0.2641509473 | 0.4836788476 |
16CBB888-B48D-42B8-9CBB-1803C1BD5EE9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 1006 | 162 | 403 | 72 | 241 | 90 | NA | 69 | 39 | 615.2062618839 | 0.2962962985 | 0.5088142157 |
1B4B27D4-681D-4E34-86C1-AF65C39613CF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 967 | 160 | 401 | 73 | 238 | 90 | NA | 67 | 36 | 625.6870801451 | 0.3653846085 | 0.509357512 |
CD7CCA99-0CE3-40D2-93E6-31CC10794FEB | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-1-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 993 | 163 | 400 | 71 | 242 | 87 | NA | 64 | 34 | 667.5089195899 | 0.314814806 | 0.5083899498 |
5F0DC88F-C7CD-4ADD-B6C1-BD0337F55649 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1163 | 171 | 425 | 85 | 251 | 89 | NA | 55 | 31 | 671.3069480349 | 0.200000003 | 0.5227858424 |
DD05EF17-9E2C-41D5-A168-845F2486CC4C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1170 | 172 | 425 | 87 | 251 | 87 | NA | 55 | 30 | 678.5840687475 | 0.1960784346 | 0.5149123669 |
DE64871C-F5FE-4593-8489-C31F16EEFA16 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1103 | 167 | 424 | 82 | 254 | 88 | NA | 54 | 31 | 674.3827495631 | 0.2156862766 | 0.5294930339 |
1C955752-B7DD-4E1C-98A6-E23F3A3CEC9B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 1093 | 168 | 400 | 78 | 237 | 85 | NA | 52 | 30 | 682.3978250685 | 0.2222222239 | 0.4964733422 |
68F7201A-7FDE-4399-9128-B61498D474E8 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 1064 | 167 | 399 | 78 | 236 | 85 | NA | 52 | 31 | 676.2367508955 | 0.2264150977 | 0.4979141355 |
CD26EBE4-4948-4F48-8003-41F5C80FEBA0 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 1041 | 168 | 399 | 78 | 235 | 86 | NA | 54 | 32 | 638.4367328684 | 0.2407407463 | 0.4913150668 |
507692B6-F147-491E-B44C-6B99AE296C3D | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 1070 | 174 | 394 | 68 | 240 | 86 | NA | 52 | 31 | 643.7872842009 | 0.2156862766 | 0.4868902564 |
B54C80ED-4A93-4926-9305-B254B3A7FA48 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 1112 | 175 | 394 | 77 | 229 | 88 | NA | 53 | 32 | 617.8299921412 | 0.2115384638 | 0.4865270257 |
CAA1DEC9-E3E4-40BF-B294-46901E7D05C2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 1073 | 174 | 397 | 78 | 234 | 85 | NA | 54 | 30 | 638.0313902369 | 0.2307692319 | 0.4870822728 |
125B35E9-E09E-4BD6-B292-23F680E2857B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 1160 | 174 | 402 | 79 | 236 | 87 | NA | 52 | 31 | 660.4008099728 | 0.1886792481 | 0.5036334991 |
D53A1831-768E-431D-9E3A-F92206909168 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 1127 | 171 | 401 | 77 | 238 | 86 | NA | 54 | 32 | 647.662567278 | 0.2264150977 | 0.4977416098 |
EE4FA714-1181-458B-9A77-4973846B1268 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 1055 | 170 | 400 | 77 | 236 | 87 | NA | 54 | 30 | 659.2449981084 | 0.2399999946 | 0.4952157438 |
3323B832-7DF4-4AF4-80A2-0EE01BC8F6B1 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 1075 | 165 | 394 | 74 | 233 | 87 | NA | 53 | 29 | 700.4498927251 | 0.1960784346 | 0.4799371958 |
395BD7EC-71A1-4EC1-83C7-249278A255DE | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 1052 | 163 | 392 | 74 | 232 | 86 | NA | 57 | 31 | 694.7446693862 | 0.1960784346 | 0.4820716381 |
B42915A2-CBFF-421C-AF9C-61AA6612D3BB | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 1080 | 167 | 388 | 73 | 230 | 85 | NA | 59 | 34 | 688.5678274891 | 0.1923076957 | 0.4823459685 |
3A5B8340-0AAD-491D-B732-B8C8B3AFFBAF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 6.5 | N | 1149 | 163 | 437 | 73 | 260 | 104 | NA | 82 | 49 | 526.3585487357 | 0.6071428657 | 0.5770122409 |
84C9A5C9-C231-4E8F-95E7-30A5A3EFC9C8 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 6.5 | N | 1070 | 160 | 443 | 73 | 244 | 126 | NA | 97 | 52 | 470.2093078433 | 0.6379310489 | 0.5860958695 |
9D482501-1B82-4B32-9E00-D4D9F82BF851 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 6.5 | N | 969 | 160 | 435 | 72 | 239 | 124 | NA | 88 | 51 | 456.5027300942 | 0.4677419364 | 0.5739159584 |
2BCD1FDF-CF6A-4DD4-8B1E-54683F191C54 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 7 | N | 1094 | 167 | 424 | 72 | 254 | 98 | NA | 81 | 41 | 572.4441022827 | 0.4909090996 | 0.556964457 |
305BA481-22E7-4E14-A8E8-8E19E9078DEA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 7 | N | 933 | 163 | 427 | 71 | 245 | 111 | NA | 89 | 56 | 474.111352302 | 0.7407407165 | 0.561950922 |
3DDAEB69-9AB0-4EE9-99A2-CE544DED5E82 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1160 | NA | NA | NA | NA | NA | 7 | N | 1042 | 165 | 427 | 71 | 250 | 106 | NA | 67 | 38 | 541.1046977949 | 0.5454545617 | 0.5610799789 |
0C074C97-F2E7-4716-A970-E41E90468379 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1120 | NA | NA | NA | NA | NA | 7.5 | N | 1116 | 167 | 432 | 73 | 251 | 108 | NA | 86 | 42 | 539.1107701002 | 0.5090909004 | 0.5698065758 |
6787100A-37DC-41C3-8D99-C063A3D72E66 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1120 | NA | NA | NA | NA | NA | 7.5 | N | 1097 | 167 | 430 | 73 | 254 | 103 | NA | 84 | 43 | 542.6386646204 | 0.4912280738 | 0.5695958734 |
EB82E369-5EDD-4D95-B0BB-6B6C2C5835B7 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1120 | NA | NA | NA | NA | NA | 7.5 | N | 1094 | 167 | 430 | 73 | 260 | 97 | NA | 83 | 41 | 560.84692969 | 0.4482758641 | 0.5686966181 |
479DC5A9-72CC-4EA8-93E0-364758908797 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1070 | NA | NA | NA | NA | NA | 8 | N | 1075 | 166 | 430 | 75 | 247 | 108 | NA | 80 | 48 | 530.2951727642 | 0.3928571343 | 0.5541411638 |
4A9880DE-B989-4BD0-876E-0C2F245707A2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1070 | NA | NA | NA | NA | NA | 8 | N | 1038 | 161 | 425 | 75 | 240 | 110 | NA | 82 | 47 | 517.3324529235 | 0.4067796469 | 0.5520953536 |
6D4484BD-FA60-4EB6-82AE-B5CE83D8DB8B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1070 | NA | NA | NA | NA | NA | 8 | N | 1089 | 165 | 429 | 75 | 247 | 107 | NA | 79 | 46 | 539.4875742282 | 0.3859649003 | 0.5602016449 |
3121F0E5-5117-4604-A777-03C3D8A165FA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1680 | NA | NA | NA | NA | NA | 12 | N | 1025 | 162 | 448 | 71 | 260 | 117 | NA | 87 | 54 | 489.8621193241 | 0.5423728824 | 0.5879015923 |
31BB0223-C382-4393-94CE-BCF0089DE8D9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1680 | NA | NA | NA | NA | NA | 12 | N | 1018 | 164 | 446 | 71 | 259 | 116 | NA | 103 | 51 | 490.4352348208 | 0.5964912176 | 0.5757172704 |
F6170E50-646F-49B4-9D5C-BE245D916A3F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1680 | NA | NA | NA | NA | NA | 12 | N | 1021 | 163 | 443 | 72 | 268 | 103 | NA | 93 | 46 | 506.4951035402 | 0.6000000238 | 0.5834070444 |
442F2EF9-7A56-4AD6-9DFE-A8BBEDD0D60C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1570 | NA | NA | NA | NA | NA | 12.5 | N | 993 | 161 | 439 | 71 | 251 | 117 | NA | 99 | 49 | 498.1721700406 | 0.6363636255 | 0.5772388577 |
BF845807-363D-4A91-AFA2-4177DD96517C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1570 | NA | NA | NA | NA | NA | 12.5 | N | 1006 | 161 | 440 | 71 | 259 | 110 | NA | 100 | 46 | 505.9890310478 | 0.6206896305 | 0.5836571455 |
E23213AD-9535-45DF-AB69-5326C1651215 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1570 | NA | NA | NA | NA | NA | 12.5 | N | 1009 | 161 | 447 | 72 | 260 | 115 | NA | 102 | 57 | 471.3084358359 | 0.7678571343 | 0.5892847776 |
3F4EBE84-0CF3-4DD8-91F8-957D160594DF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1620 | NA | NA | NA | NA | NA | 13 | N | 1030 | 165 | 445 | 71 | 259 | 115 | NA | 92 | 58 | 499.5228538042 | 0.6206896305 | 0.5876902938 |
9E39935B-1BF3-435E-B468-25D3256777E9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1620 | NA | NA | NA | NA | NA | 13 | N | 1048 | 165 | 444 | 71 | 261 | 112 | NA | 98 | 55 | 496.5162780261 | 0.6666666865 | 0.5803356767 |
BDBAD607-6813-42AB-9FDC-91CD1907D39F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1620 | NA | NA | NA | NA | NA | 13 | N | 1034 | 164 | 442 | 72 | 253 | 117 | NA | 93 | 54 | 510.6225331681 | 0.7017543912 | 0.5852968097 |
5ECC8182-4CF4-41DF-99CB-D036F45CD605 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1430 | NA | NA | NA | NA | NA | 13.5 | N | 1013 | 165 | 426 | 71 | 253 | 102 | NA | 88 | 46 | 559.3562995596 | 0.553571403 | 0.5503824353 |
B4F28AF3-AD1E-4932-961E-D6ADD03CFE8B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1430 | NA | NA | NA | NA | NA | 13.5 | N | 976 | 163 | 421 | 71 | 250 | 100 | NA | 85 | 45 | 572.9217930156 | 0.5660377145 | 0.5480290651 |
EAB1565C-FE53-4D80-AD6C-7D9EE456D05D | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | 1430 | NA | NA | NA | NA | NA | 13.5 | N | 983 | 162 | 426 | 71 | 253 | 102 | NA | 88 | 43 | 573.303453527 | 0.6037735939 | 0.5572606921 |
18C06031-912A-4F2F-8CE4-E986DD99EFEC | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1098 | 166 | 425 | 82 | 252 | 91 | NA | 59 | 33 | 603.2225681242 | 0.3076923192 | 0.5351366401 |
86E518B8-5756-4657-9BE0-06DDEABA0014 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1141 | 165 | 425 | 85 | 242 | 98 | NA | 60 | 36 | 566.2342500877 | 0.3703703582 | 0.5423698425 |
D8AB70FF-2B62-4F8B-AB5F-A9003A4F9861 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-2-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1107 | 169 | 425 | 85 | 247 | 93 | NA | 59 | 32 | 608.8556232668 | 0.3333333433 | 0.5352771878 |
398E5506-6D7B-4AEA-9875-9535B9084984 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1094 | 166 | 414 | 85 | 243 | 86 | NA | 54 | 30 | 695.5109217201 | 0.1800000072 | 0.523627758 |
92330079-514D-4125-83F9-1E41F6064DE3 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1138 | 169 | 414 | 86 | 242 | 86 | NA | 53 | 30 | 680.9173492912 | 0.1764705926 | 0.5143088698 |
CEE17EE8-D43B-4463-B631-7E1906073B22 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1111 | 169 | 414 | 85 | 241 | 88 | NA | 55 | 31 | 671.2248972939 | 0.2199999988 | 0.5238150954 |
2DE65F83-5665-4C54-84F8-E38642ABCB11 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 900 | NA | NA | NA | NA | 1.5 | N | 922 | 163 | 376 | 78 | 211 | 87 | NA | 51 | 32 | 616.2550505932 | 0.2653061152 | 0.4687297046 |
D5F743C3-B431-46F2-9E0C-48A204EF782C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 900 | NA | NA | NA | NA | 1.5 | N | 1074 | 167 | 390 | 80 | 220 | 90 | NA | 53 | 33 | 635.5528732607 | 0.2115384638 | 0.4711805284 |
F021D25C-E815-4396-91AD-21C00835C59A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 900 | NA | NA | NA | NA | 1.5 | N | 1075 | 165 | 386 | 80 | 217 | 89 | NA | 55 | 30 | 630.3416943297 | 0.1698113233 | 0.4681928456 |
43570F56-D20D-41BE-AFCA-34E1C257E5A1 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2 | N | 1044 | 166 | 377 | 80 | 210 | 87 | NA | 49 | 28 | 712.516632687 | 0.1632653028 | 0.4379416704 |
E0B1C62E-883E-47FE-966C-806F17C1DECD | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2 | N | 1112 | 169 | 382 | 81 | 217 | 84 | NA | 51 | 29 | 704.2746920911 | 0.200000003 | 0.4632142484 |
EA70AB8C-2368-416D-AB58-E4B20217B2F8 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2 | N | 1058 | 168 | 379 | 80 | 214 | 85 | NA | 48 | 31 | 693.1060263137 | 0.1800000072 | 0.4555298686 |
379B0E6B-A7F7-4F49-99E3-CAE72D7C6B56 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1000 | NA | NA | NA | NA | 2.5 | N | 1116 | 169 | 390 | 79 | 225 | 86 | NA | 49 | 29 | 715.9907033603 | 0.1568627506 | 0.4833812118 |
49525B6B-A8F3-41F3-B39F-83F9BD79CC4F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1000 | NA | NA | NA | NA | 2.5 | N | 1029 | 163 | 385 | 78 | 221 | 86 | NA | 50 | 29 | 704.3870995804 | 0.2291666716 | 0.4785404205 |
898498F2-CF36-4102-BDF1-BEB569EA831A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 1000 | NA | NA | NA | NA | 2.5 | N | 1072 | 162 | 388 | 79 | 225 | 84 | NA | 51 | 30 | 677.808225132 | 0.2199999988 | 0.4755049944 |
39D4BA66-5074-484F-93CA-6589186EBF4E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 1049 | 161 | 381 | 79 | 219 | 83 | NA | 47 | 27 | 779.7181519919 | 0.1632653028 | 0.4538539648 |
86141953-3FD4-417F-B609-61DC8F5DCB34 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 1045 | 160 | 385 | 78 | 224 | 83 | NA | 46 | 29 | 762.6156877023 | 0.1599999964 | 0.4793850482 |
96BD9D67-E851-42B5-8983-2C426F2125A5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 1069 | 166 | 385 | 79 | 226 | 80 | NA | 46 | 28 | 766.4455396739 | 0.1875 | 0.4711319506 |
3B185BE1-AA9D-4067-9F3B-812C1E238762 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 447 | 1450 | NA | NA | NA | NA | 6.5 | N | 962 | 159 | 374 | 76 | 207 | 91 | NA | 55 | 36 | 639.5832774439 | 0.1960784346 | 0.4638957679 |
5A05C8F1-B8E6-407B-AB27-CE72C53DEF35 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 447 | 1450 | NA | NA | NA | NA | 6.5 | N | 952 | 157 | 370 | 77 | 203 | 90 | NA | 55 | 38 | 645.1415356285 | 0.200000003 | 0.4559143782 |
6F486127-3DB1-46CC-9D98-ED557429D010 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 447 | 1450 | NA | NA | NA | NA | 6.5 | N | 890 | 159 | 370 | 76 | 205 | 89 | NA | 55 | 34 | 631.788127947 | 0.2244897932 | 0.4598039389 |
4CD4B566-D3E6-428A-82F8-DC92D3AE27F5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 630 | 2160 | NA | NA | NA | NA | 7 | N | 1005 | 157 | 379 | 77 | 209 | 93 | NA | 56 | 36 | 667.5377019209 | 0.1764705926 | 0.4650630653 |
833C1B9F-6814-44F5-A659-DA7D24CCA20E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 630 | 2160 | NA | NA | NA | NA | 7 | N | 916 | 159 | 367 | 76 | 199 | 92 | NA | 56 | 39 | 627.2735327567 | 0.1764705926 | 0.4568757415 |
9A3B8546-93BF-4B55-8A0F-321C1659CF57 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 630 | 2160 | NA | NA | NA | NA | 7 | N | 952 | 155 | 378 | 75 | 204 | 99 | NA | 55 | 41 | 574.3178647854 | 0.2599999905 | 0.4687643647 |
64D6D6D6-BAF9-403C-A83A-54EF08EB8219 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 659 | 1970 | NA | NA | NA | NA | 7.5 | N | 908 | 158 | 373 | 75 | 205 | 93 | NA | 49 | 40 | 616.5212962411 | 0.2156862766 | 0.4750114083 |
C7966E84-3192-4753-816E-320AEDF5070F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 659 | 1970 | NA | NA | NA | NA | 7.5 | N | 960 | 156 | 377 | 76 | 205 | 96 | NA | 56 | 41 | 606.9716181068 | 0.2075471729 | 0.4833538234 |
E7F728C9-6AFF-40CD-95FB-2B99F2ACD8A6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 659 | 1970 | NA | NA | NA | NA | 7.5 | N | 898 | 159 | 373 | 76 | 205 | 92 | NA | 54 | 45 | 614.5362461197 | 0.2199999988 | 0.4724853039 |
30A4442D-2668-49DE-A95F-343DD554A4A0 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 919 | 1480 | NA | NA | NA | NA | 8 | N | 1012 | 163 | 389 | 73 | 222 | 94 | NA | 61 | 37 | 666.1122605375 | 0.2181818187 | 0.4909256995 |
430F0595-DC6C-4D41-AB0F-8F97982D8CB1 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 919 | 1480 | NA | NA | NA | NA | 8 | N | 977 | 162 | 390 | 75 | 222 | 93 | NA | 64 | 39 | 652.8376744202 | 0.2641509473 | 0.4946397543 |
74B58E1E-B1F5-4907-946F-7EEEBA26ABB6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 919 | 1480 | NA | NA | NA | NA | 8 | N | 976 | 163 | 389 | 73 | 223 | 93 | NA | 62 | 40 | 648.5134371611 | 0.2592592537 | 0.4999325275 |
4FB291FF-6A45-4148-A18F-54671F665971 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2190 | 1850 | NA | NA | NA | NA | 12 | N | 968 | 161 | 408 | 75 | 223 | 110 | NA | 76 | 53 | 547.9670765882 | 0.629629612 | 0.5548155308 |
BE13634E-CFDC-4385-8E64-0BA4D3DF63E4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2190 | 1850 | NA | NA | NA | NA | 12 | N | 944 | 164 | 405 | 74 | 224 | 107 | NA | 74 | 54 | 563.2995037817 | 0.537037015 | 0.538598299 |
ECA1A484-E39B-4D24-AD1A-3C435877C7BA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2190 | 1850 | NA | NA | NA | NA | 12 | N | 985 | 164 | 406 | 74 | 225 | 107 | NA | 79 | 50 | 563.4227123562 | 0.5961538553 | 0.5517032146 |
43B20DEF-0A1B-4E1E-9965-70543D0F7F74 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2130 | NA | NA | NA | NA | 12.5 | N | 975 | 162 | 402 | 75 | 213 | 114 | NA | 66 | 60 | 552.6002380133 | 0.4181818068 | 0.5380590558 |
4D0CD717-F4B4-4BE9-9FD3-20A77EE1735B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2130 | NA | NA | NA | NA | 12.5 | N | 907 | 162 | 397 | 75 | 207 | 115 | NA | 58 | 52 | 533.6565788226 | 0.6470588446 | 0.5208232999 |
AE006D9E-94D2-4190-BD89-ACFB7273963C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2130 | NA | NA | NA | NA | 12.5 | N | 958 | 162 | 397 | 76 | 209 | 112 | NA | 66 | 56 | 551.0769211701 | 0.400000006 | 0.5268822312 |
11D35C8C-9FD9-4F11-A8E5-54D2D3583B43 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2090 | NA | NA | NA | NA | 13 | N | 923 | 159 | 398 | 75 | 208 | 115 | NA | 66 | 61 | 524.8528160146 | 0.5576922894 | 0.5303644538 |
C269ED96-6A73-4CBD-BD9C-1361F2F34FDC | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2090 | NA | NA | NA | NA | 13 | N | 925 | 161 | 397 | 74 | 213 | 110 | NA | 60 | 52 | 530.3044432776 | 0.5094339848 | 0.5345568657 |
D88BA954-12FE-44F9-B1C8-F1F67EDFDF29 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 2110 | 2090 | NA | NA | NA | NA | 13 | N | 936 | 161 | 396 | 74 | 211 | 111 | NA | 69 | 57 | 534.7221093829 | 0.538461566 | 0.5320903659 |
5037070A-01DF-46F2-9706-631BD27B9DE3 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 1930 | 1650 | NA | NA | NA | NA | 13.5 | N | 966 | 160 | 404 | 73 | 227 | 104 | NA | 80 | 41 | 596.621996524 | 0.4814814925 | 0.5318546891 |
78A8F18A-82C0-420E-9A0E-246E7B48037A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 1930 | 1650 | NA | NA | NA | NA | 13.5 | N | 971 | 160 | 406 | 73 | 233 | 100 | NA | 78 | 41 | 597.2420367417 | 0.5882353187 | 0.5400696993 |
EA1B8E17-A9D2-42F3-A9FF-787337B1ECB4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | 1930 | 1650 | NA | NA | NA | NA | 13.5 | N | 1012 | 165 | 407 | 70 | 235 | 102 | NA | 77 | 48 | 589.1457134729 | 0.519230783 | 0.5377105474 |
2F84E668-D0DB-476C-B706-9796034334DA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1068 | 168 | 408 | 87 | 230 | 91 | NA | 55 | 31 | 667.6582882166 | 0.269230783 | 0.5058072209 |
99E8FB2D-5B81-49AC-8A02-B988211AC80C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1033 | 146 | 416 | 82 | 238 | 96 | NA | 60 | 34 | 624.3316479716 | 0.2857142985 | 0.5272801518 |
E93EE344-E2C7-4BBF-B333-70D10C032B2D | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-3-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1072 | 152 | 412 | 86 | 235 | 91 | NA | 56 | 33 | 653.7129505687 | 0.3090909123 | 0.5175956488 |
4890740D-FE99-485A-992B-74364E646064 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1110 | 162 | 417 | 76 | 250 | 91 | NA | 62 | 35 | 639.311233242 | 0.1698113233 | 0.5188785791 |
781F263F-DCEA-4452-AF5F-C4400A1020EE | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1105 | 164 | 419 | 75 | 251 | 93 | NA | 60 | 35 | 620.8348987079 | 0.1509433985 | 0.5274561644 |
D563595F-6F32-4BB4-9BC3-A07A3F60C490 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1100 | 164 | 415 | 76 | 249 | 90 | NA | 62 | 35 | 640.1003899731 | 0.1851851791 | 0.5124615431 |
5B7FD75F-6224-4C14-8A4A-57D9EB90932C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3360 | 208 | NA | 1.5 | N | 974 | 163 | 396 | 73 | 230 | 93 | NA | 69 | 38 | 564.0220446649 | 0.2727272809 | 0.5019475818 |
D5D3F2F9-182A-4DE4-AF46-83F924ED163F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3360 | 208 | NA | 1.5 | N | 989 | 164 | 398 | 70 | 238 | 90 | NA | 70 | 37 | 578.4389388298 | 0.3207547069 | 0.5085486174 |
FDE93902-C0D0-48FD-8BE9-816C5D60FADD | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3360 | 208 | NA | 1.5 | N | 976 | 162 | 396 | 73 | 232 | 91 | NA | 69 | 39 | 563.2382663598 | 0.2321428508 | 0.5044977069 |
4FC2DD55-4361-4D5B-8ED3-782FCEF16DB5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4960 | 523 | NA | 2 | N | 913 | 148 | 393 | 69 | 231 | 93 | NA | 72 | 38 | 561.4951683333 | 0.2962962985 | 0.4934787452 |
C63A6E83-E07F-4C79-AA41-149E8042D91E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4960 | 523 | NA | 2 | N | 918 | 154 | 392 | 67 | 234 | 91 | NA | 71 | 37 | 566.5867602777 | 0.2884615362 | 0.4975182414 |
C8990C9D-B302-4BA7-8DDD-E27BB3CFEDF2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4960 | 523 | NA | 2 | N | 938 | 154 | 391 | 69 | 232 | 90 | NA | 69 | 37 | 582.0343960915 | 0.2678571343 | 0.5002655983 |
4DA4529E-4CF2-40F7-8992-2B464D9DAE76 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4050 | 715 | NA | 2.5 | N | 950 | 149 | 393 | 70 | 230 | 93 | NA | 67 | 37 | 567.6701296998 | 0.2962962985 | 0.4945983887 |
7F24B510-9C5E-4848-9897-74145043E052 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4050 | 715 | NA | 2.5 | N | 951 | 159 | 391 | 70 | 231 | 90 | NA | 63 | 37 | 592.3958410945 | 0.2363636345 | 0.4818996787 |
EC4F786C-3D52-4291-A180-4F9F65B84A14 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4050 | 715 | NA | 2.5 | N | 990 | 161 | 399 | 70 | 234 | 95 | NA | 67 | 36 | 572.6543197613 | 0.2363636345 | 0.5107373595 |
155292EC-B922-4F2A-A062-3B3C2631A3CE | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3820 | 716 | NA | 3 | N | 1018 | 160 | 398 | 73 | 233 | 92 | NA | 58 | 37 | 626.0982626974 | 0.1851851791 | 0.5137252212 |
6CED3AF0-8395-4710-9358-C7A43E6431E2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3820 | 716 | NA | 3 | N | 1029 | 162 | 395 | 71 | 235 | 89 | NA | 58 | 38 | 631.0974304202 | 0.1886792481 | 0.5120312572 |
C3DE4A41-5036-4625-BAAE-F8CBC2046BD3 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 3820 | 716 | NA | 3 | N | 1027 | 162 | 397 | 71 | 237 | 89 | NA | 61 | 35 | 635.4093992313 | 0.1481481493 | 0.5138025284 |
1F64CF10-F01F-4FE2-B894-B088F53EE802 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6820 | 915 | NA | 6.5 | N | 941 | 161 | 404 | 72 | 224 | 108 | NA | 67 | 45 | 513.6003681936 | 0.2068965584 | 0.5129628181 |
472A59E6-0E93-4B99-8AFC-6306B839E259 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6820 | 915 | NA | 6.5 | N | 914 | 155 | 404 | 73 | 227 | 104 | NA | 64 | 43 | 532.1085275307 | 0.2321428508 | 0.5031293035 |
F8193ECE-38C0-43C6-90BE-29B5A125D9B6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6820 | 915 | NA | 6.5 | N | 897 | 152 | 397 | 68 | 230 | 99 | NA | 70 | 43 | 525.3995798593 | 0.2456140369 | 0.5005602837 |
07554931-AECF-4026-A051-76F288DABDB5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7950 | 1260 | NA | 7 | N | 863 | 159 | 405 | 70 | 230 | 105 | NA | 72 | 44 | 506.4889131425 | 0.3703703582 | 0.5135917068 |
96607D61-89B8-4B0D-85FD-66DABF252E0B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7950 | 1260 | NA | 7 | N | 844 | 159 | 399 | 69 | 228 | 102 | NA | 74 | 40 | 510.6761010954 | 0.3636363745 | 0.5034765601 |
F9301603-762E-44A8-96D4-D139FDED2352 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7950 | 1260 | NA | 7 | N | 860 | 160 | 406 | 71 | 231 | 104 | NA | 74 | 46 | 496.9635142153 | 0.3454545438 | 0.5110087395 |
3B572E5F-7733-48EC-A31F-46651DFBB72C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6330 | 1440 | NA | 7.5 | N | 972 | 162 | 418 | 69 | 248 | 101 | NA | 71 | 43 | 524.1560946391 | 0.3272727132 | 0.5369175076 |
4C1B8CA9-2C7E-41BC-BE7E-FA2EB386FCEF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6330 | 1440 | NA | 7.5 | N | 1012 | 162 | 411 | 70 | 240 | 101 | NA | 69 | 44 | 553.0966655364 | 0.2857142985 | 0.5265833735 |
D6356AEA-1041-45A7-9A2E-EBAC0346D7B6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6330 | 1440 | NA | 7.5 | N | 967 | 161 | 420 | 70 | 246 | 104 | NA | 75 | 43 | 517.0468203846 | 0.3448275924 | 0.5421097279 |
A135E9EE-CF77-4CFE-9721-13CAE37CE878 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6590 | 1390 | NA | 8 | N | 888 | 156 | 397 | 71 | 226 | 100 | NA | 64 | 44 | 538.5563888287 | 0.2280701697 | 0.5012101531 |
B08F535A-F45E-4D44-A1A8-5417C8C030AC | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6590 | 1390 | NA | 8 | N | 955 | 157 | 406 | 73 | 231 | 102 | NA | 62 | 44 | 558.8336215742 | 0.2241379321 | 0.5113189816 |
C36BE2E0-E056-4A1E-B47A-CCD3D92A302A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6590 | 1390 | NA | 8 | N | 959 | 161 | 402 | 72 | 230 | 100 | NA | 64 | 41 | 580.7979055836 | 0.2363636345 | 0.5043450594 |
1E581C60-53FA-4134-A1C7-4CF9A9CDC413 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5500 | 863 | 54.8 | 12 | N | 949 | 168 | 409 | 73 | 223 | 113 | NA | 67 | 50 | 504.8758562567 | 0.3333333433 | 0.5360300541 |
69F0AB4F-58F9-4DB3-A9D4-497684B39BDF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5500 | 863 | 54.8 | 12 | N | 956 | 169 | 409 | 73 | 229 | 107 | NA | 67 | 44 | 540.3666421244 | 0.2857142985 | 0.5330983996 |
BBE88F5A-CE01-48F7-A5E7-3085B04D3567 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5500 | 863 | 54.8 | 12 | N | 932 | 168 | 407 | 73 | 226 | 108 | NA | 68 | 45 | 533.3556615604 | 0.2909090817 | 0.5284702182 |
44385707-9A1B-4029-A8A6-084B960FDA84 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6240 | 1180 | 83.6 | 12.5 | N | 872 | 175 | 394 | 70 | 216 | 108 | NA | 68 | 50 | 511.5046455844 | 0.3157894611 | 0.5100628734 |
4A95AC22-FAA7-4780-996C-8FC9A8E16B46 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6240 | 1180 | 83.6 | 12.5 | N | 879 | 178 | 402 | 71 | 221 | 110 | NA | 73 | 45 | 500.1263114844 | 0.3389830589 | 0.5195542574 |
5C302FFB-5063-4FE2-A2BB-08D24EB52E43 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6240 | 1180 | 83.6 | 12.5 | N | 911 | 177 | 403 | 72 | 222 | 109 | NA | 67 | 47 | 530.6100409683 | 0.3103448153 | 0.5101313591 |
0422B7EE-F533-4868-8927-D0B69201DD6C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6050 | 1270 | 84.5 | 13 | N | 872 | 177 | 408 | 72 | 221 | 115 | NA | 72 | 49 | 485.3701897471 | 0.3454545438 | 0.5157992244 |
5392B8BF-2939-41B4-B6ED-65E234140545 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6050 | 1270 | 84.5 | 13 | N | 939 | 177 | 411 | 70 | 227 | 114 | NA | 71 | 48 | 502.9002097771 | 0.3103448153 | 0.5268825889 |
862F322E-0205-463C-8B07-ECF018E169B5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6050 | 1270 | 84.5 | 13 | N | 936 | 175 | 411 | 71 | 228 | 112 | NA | 72 | 49 | 507.7646424961 | 0.2931034565 | 0.51930058 |
21EA0D9D-E224-4AD9-BEA6-A0956022E6EF | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5540 | 1280 | 69.1 | 13.5 | N | 810 | 169 | 398 | 72 | 219 | 107 | NA | 63 | 48 | 553.0614561705 | 0.2295081913 | 0.5159279108 |
749E4C75-FB70-48B9-B1CF-9E34C064D3BB | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5540 | 1280 | 69.1 | 13.5 | N | 911 | 169 | 400 | 71 | 219 | 110 | NA | 64 | 45 | 544.0273366977 | 0.1929824501 | 0.5001513362 |
F228830D-1783-49C0-B938-0ED257F2046C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 5540 | 1280 | 69.1 | 13.5 | N | 861 | 172 | 400 | 70 | 223 | 107 | NA | 66 | 45 | 525.9938967555 | 0.314814806 | 0.5144155025 |
32ECCD1A-D0D9-4D14-9B81-6E7C1D0E1C7E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 1127 | 166 | 447 | 70 | 257 | 120 | NA | 68 | 44 | 500.1396676121 | 0.3898304999 | 0.5626063347 |
75E66C49-AD0A-4419-93B0-26C20B9A7009 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 1095 | 166 | 448 | 73 | 260 | 115 | NA | 67 | 45 | 512.9341378342 | 0.360655725 | 0.5695276856 |
A860A625-23B6-4D06-AB2F-6DE355FF8F5E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-4-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 1138 | 165 | 447 | 72 | 261 | 114 | NA | 69 | 42 | 520.2424658466 | 0.3442623019 | 0.5632929206 |
427E93C0-E6FA-4A94-88A5-1D89E34ACBDB | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1135 | 153 | 412 | 68 | 256 | 88 | NA | 52 | 33 | 613.6289241997 | 0.2363636345 | 0.5305536389 |
858707C0-5A9E-4749-9977-85AC362C8EA4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1092 | 154 | 410 | 68 | 254 | 88 | NA | 52 | 33 | 624.0005322255 | 0.2222222239 | 0.5193823576 |
9522D42A-25B6-4F6C-BF5D-7C913F8656AA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 1071 | 144 | 413 | 69 | 257 | 87 | NA | 55 | 32 | 619.2785147412 | 0.2181818187 | 0.5360149741 |
560AC590-53E8-4C45-8687-018E7724530C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 624 | NA | NA | NA | 1.5 | N | 952 | 165 | 365 | 73 | 209 | 83 | NA | 59 | 32 | 657.061607672 | 0.2083333284 | 0.4393973947 |
8869425B-E1DE-42CE-93F2-8654C9ACED9F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 624 | NA | NA | NA | 1.5 | N | 904 | 165 | 363 | 73 | 207 | 83 | NA | 56 | 30 | 667.0433145859 | 0.1632653028 | 0.4574406445 |
8C97F731-413E-4448-BD04-2FAE34805636 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 624 | NA | NA | NA | 1.5 | N | 913 | 164 | 363 | 74 | 208 | 81 | NA | 58 | 30 | 677.6433302554 | 0.1568627506 | 0.4363828599 |
0C0ADDE0-A8FB-4A2C-A9C8-0F9A12CB7643 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 715 | NA | NA | NA | 2 | N | 972 | 163 | 364 | 69 | 211 | 84 | NA | 61 | 32 | 702.1815545642 | 0.1599999964 | 0.4336230159 |
C2FF3196-AD9E-464A-82A4-75164E5C6640 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 715 | NA | NA | NA | 2 | N | 1049 | 169 | 370 | 70 | 215 | 85 | NA | 62 | 34 | 687.4475673212 | 0.2083333284 | 0.4510007799 |
FCF9FC8E-B4E9-4954-9136-30BC637FC7C2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 715 | NA | NA | NA | 2 | N | 895 | 166 | 357 | 68 | 206 | 83 | NA | 60 | 29 | 696.2985198967 | 0.1428571492 | 0.4282984436 |
2E086B59-7F7A-42FA-AF11-80EE5C37557C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 724 | NA | NA | NA | 2.5 | N | 1004 | 163 | 375 | 71 | 216 | 88 | NA | 64 | 34 | 644.9212698005 | 0.2244897932 | 0.4579455256 |
5089DBA5-7D5A-4471-A6F4-8A3C8BB7A06B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 724 | NA | NA | NA | 2.5 | N | 991 | 164 | 374 | 69 | 217 | 88 | NA | 62 | 35 | 642.4781705891 | 0.200000003 | 0.4583716691 |
53181139-DE87-411E-86E1-11921F8661F0 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 724 | NA | NA | NA | 2.5 | N | 1044 | 167 | 378 | 70 | 220 | 88 | NA | 63 | 35 | 658.5672289898 | 0.1666666716 | 0.4520494044 |
157B98F4-0317-4835-9269-7FFA67302861 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 677 | NA | NA | NA | 3 | N | 1034 | 166 | 367 | 71 | 214 | 82 | NA | 55 | 30 | 757.872736571 | 0.1599999964 | 0.4274139702 |
3558FAED-CE59-4206-A111-B12656DD269A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 677 | NA | NA | NA | 3 | N | 989 | 160 | 371 | 73 | 214 | 84 | NA | 57 | 30 | 728.9008564061 | 0.1568627506 | 0.447265029 |
84D488D0-CCFC-4A8D-ACB4-13024087DBF4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | 677 | NA | NA | NA | 3 | N | 1014 | 162 | 371 | 74 | 214 | 83 | NA | 54 | 31 | 734.5906547696 | 0.1599999964 | 0.4440048635 |
33D0C4F2-9DC9-47D2-B8E2-3C79E269C3C7 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1380 | NA | 858 | NA | NA | NA | 6.5 | N | 978 | 162 | 390 | 72 | 216 | 102 | NA | 63 | 46 | 569.2888903941 | 0.2727272809 | 0.5093219876 |
84DC8EED-7EA8-4600-83BE-D7D50183808B | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1380 | NA | 858 | NA | NA | NA | 6.5 | N | 980 | 161 | 387 | 72 | 217 | 98 | NA | 62 | 43 | 577.3778667508 | 0.2413793057 | 0.5136354566 |
C5C15F06-00B4-4A75-A156-F8F5825A9A21 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1380 | NA | 858 | NA | NA | NA | 6.5 | N | 900 | 160 | 386 | 72 | 216 | 98 | NA | 62 | 46 | 558.1354739807 | 0.3518518507 | 0.5182875991 |
CE9EB2EC-320C-4222-9874-DBDC2D7B659E | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1370 | NA | 951 | NA | NA | NA | 7 | N | 1009 | 163 | 395 | 71 | 215 | 109 | NA | 71 | 55 | 534.4520759763 | 0.3275862038 | 0.5286039114 |
D825C804-E24C-451E-851A-B90F68D4CFBD | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1370 | NA | 951 | NA | NA | NA | 7 | N | 947 | 165 | 397 | 72 | 215 | 110 | NA | 69 | 55 | 513.7660798395 | 0.4210526347 | 0.5243612528 |
DF408631-D520-4A6B-80B6-A99C61DC12C5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1370 | NA | 951 | NA | NA | NA | 7 | N | 949 | 162 | 391 | 71 | 216 | 104 | NA | 71 | 49 | 547.6975708379 | 0.3859649003 | 0.5178886652 |
0381E29B-6A86-4999-94F1-BF024AFA5FC9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1280 | NA | 953 | NA | NA | NA | 7.5 | N | 954 | 160 | 392 | 69 | 224 | 99 | NA | 71 | 42 | 580.7934284919 | 0.4181818068 | 0.511803329 |
319E54DE-CB6C-4F19-99FE-F839E074826A | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1280 | NA | 953 | NA | NA | NA | 7.5 | N | 990 | 164 | 396 | 71 | 226 | 99 | NA | 70 | 47 | 592.6112082835 | 0.3962264061 | 0.5217431188 |
C2FDC3B7-E285-4CDD-ABB8-C70E873B32DA | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1280 | NA | 953 | NA | NA | NA | 7.5 | N | 986 | 161 | 394 | 70 | 228 | 96 | NA | 75 | 40 | 608.9454957931 | 0.3818181753 | 0.5140162706 |
32CB5FB4-863C-4BCF-BB91-35060D473186 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1250 | NA | 930 | NA | NA | NA | 8 | N | 926 | 161 | 383 | 72 | 215 | 96 | NA | 63 | 38 | 624.3528501718 | 0.2592592537 | 0.4887167811 |
CCDB0741-F421-44B8-860B-C4D1124B3207 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1250 | NA | 930 | NA | NA | NA | 8 | N | 911 | 159 | 386 | 73 | 219 | 94 | NA | 63 | 35 | 634.4829756638 | 0.2592592537 | 0.485586673 |
E608F09F-720D-464B-9246-806199CA914C | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1250 | NA | 930 | NA | NA | NA | 8 | N | 972 | 159 | 385 | 73 | 221 | 91 | NA | 60 | 32 | 698.0688767568 | 0.1666666716 | 0.4758661389 |
2DB2CBE7-B6F2-419E-AD79-4BEEBEBE2057 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1430 | NA | NA | NA | 12 | N | 904 | 160 | 382 | 72 | 205 | 105 | NA | 63 | 39 | 634.585047622 | 0.137931034 | 0.4792592525 |
56D6B1C3-93C9-46F7-A5EE-A0AC4B1420F9 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1430 | NA | NA | NA | 12 | N | 841 | 160 | 379 | 72 | 201 | 106 | NA | 55 | 52 | 600.6257400282 | 0.2830188572 | 0.4845821559 |
C1584A55-35EE-4D95-8E0A-A1BC64C1229F | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1430 | NA | NA | NA | 12 | N | 852 | 159 | 378 | 72 | 199 | 107 | NA | 60 | 49 | 612.438637209 | 0.1694915295 | 0.4836847484 |
0319214B-1559-4B14-8252-6659E91A480D | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1940 | NA | 1520 | NA | NA | NA | 12.5 | N | 939 | 162 | 390 | 69 | 216 | 105 | NA | 65 | 47 | 644.3833127712 | 0.3333333433 | 0.5127341747 |
2BB2026F-62FE-4D8C-80EF-1F1C0CB9B3F2 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1940 | NA | 1520 | NA | NA | NA | 12.5 | N | 849 | 161 | 380 | 71 | 205 | 104 | NA | 68 | 45 | 629.3487045553 | 0.2678571343 | 0.4934401214 |
5EE14334-DC40-4FB1-99EB-01755D033D96 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1940 | NA | 1520 | NA | NA | NA | 12.5 | N | 852 | 161 | 388 | 72 | 210 | 106 | NA | 67 | 45 | 625.1050430181 | 0.3272727132 | 0.4962767363 |
23AC224F-3F54-4174-A484-429CFA7CE8E5 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1550 | NA | NA | NA | 13 | N | 944 | 162 | 391 | 72 | 209 | 110 | NA | 60 | 53 | 616.5077684103 | 0.2280701697 | 0.5064709187 |
7FB3D3C2-9C9A-4447-8F2D-FC45A56D50E4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1550 | NA | NA | NA | 13 | N | 944 | 157 | 397 | 73 | 210 | 114 | NA | 57 | 56 | 606.5199537027 | 0.1833333373 | 0.5153920054 |
86DDC8F8-3998-49AF-A88C-6FD1769A94D6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1550 | NA | NA | NA | 13 | N | 943 | 158 | 394 | 73 | 210 | 111 | NA | 59 | 53 | 629.9813650943 | 0.2203389853 | 0.5134862065 |
A58283A9-8D31-42E8-9EFF-D73FCB540AD6 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1570 | NA | NA | NA | 13.5 | N | 895 | 158 | 386 | 72 | 204 | 110 | NA | 64 | 51 | 597.1485341579 | 0.2678571343 | 0.4940763116 |
B1B913CE-E3F8-411F-B646-54C84C2E9778 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1570 | NA | NA | NA | 13.5 | N | 872 | 159 | 388 | 72 | 205 | 111 | NA | 60 | 53 | 596.8090894379 | 0.2807017565 | 0.4994857609 |
BA2CA502-D346-4380-B515-ABBA32578EF4 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | 1960 | NA | 1570 | NA | NA | NA | 13.5 | N | 923 | 158 | 388 | 72 | 206 | 110 | NA | 61 | 51 | 619.9157406261 | 0.2142857164 | 0.4998833537 |
121B4FA8-E52C-4F88-B520-505D8FB987ED | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1042 | 164 | 397 | 68 | 238 | 91 | NA | 68 | 36 | 714.8964384227 | 0.2830188572 | 0.5044236183 |
22780E0E-4D34-491D-A76B-7EA1471C600D | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1047 | 165 | 398 | 68 | 239 | 91 | NA | 70 | 37 | 688.1258197959 | 0.3333333433 | 0.4991211295 |
DE6CA1B3-3279-4CA7-8BD6-F897BB5D3F87 | 2001 | M | 21 | 175 | 60.3 | 125 | 69.33 | BLACK OR AFRICAN AMERICAN | NOT HISPANIC OR LATINO | E-A-B-D-C | PERIOD-5-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 1068 | 164 | 399 | 69 | 240 | 90 | NA | 67 | 36 | 722.7663311603 | 0.2592592537 | 0.4979297817 |
10EB996F-03F7-4E13-BD49-EB03700A360B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 896 | 172 | 382 | 89 | 220 | 73 | NA | 43 | 27 | 716.818925914 | 0.1395348907 | 0.3402266204 |
350779C1-3425-4339-865D-508E6C328C1D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 847 | 171 | 379 | 89 | 218 | 72 | NA | 48 | 28 | 691.712267015 | 0.1395348907 | 0.3520620465 |
AFA2F720-8457-4D58-B778-381708E45C23 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 830 | 171 | 375 | 89 | 214 | 72 | NA | 43 | 26 | 683.0285779522 | 0.1707317084 | 0.3399906754 |
00B0AC34-2410-4659-8356-DBBB8F554BF1 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 532 | NA | NA | NA | 1.5 | N | 787 | 165 | 346 | 86 | 186 | 74 | NA | 47 | 29 | 622.3550555196 | 0.1162790731 | 0.3060350418 |
98B0BDF5-D22B-43FB-AD1E-E41FAAFD7433 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 532 | NA | NA | NA | 1.5 | N | 758 | 167 | 345 | 88 | 184 | 73 | NA | 44 | 27 | 608.6888313376 | 0.1395348907 | 0.3000395596 |
C2F6E560-0046-4C81-AC9B-054BB6564BCE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 532 | NA | NA | NA | 1.5 | N | 790 | 167 | 346 | 86 | 187 | 73 | NA | 48 | 28 | 622.8941460205 | 0.095238097 | 0.2929250598 |
11EE6587-27D5-4E1C-BC2C-5F6E45244A73 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 616 | NA | NA | NA | 2 | N | 751 | 161 | 346 | 88 | 188 | 70 | NA | 43 | 25 | 632.3608779804 | 0.1395348907 | 0.2946071625 |
41294309-CA9B-4A7D-BA92-BAE6F56D773A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 616 | NA | NA | NA | 2 | N | 724 | 176 | 340 | 86 | 182 | 72 | NA | 44 | 26 | 632.7158529072 | 0.1395348907 | 0.2980771065 |
97A10C5B-2BAD-460D-925E-1E178F52A8FE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 616 | NA | NA | NA | 2 | N | 802 | 164 | 348 | 86 | 190 | 72 | NA | 47 | 27 | 651.9603493882 | 0.1395348907 | 0.2988874316 |
7841F1D3-F947-4DE9-A83D-53EE93CA9A8E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 691 | NA | NA | NA | 2.5 | N | 737 | 167 | 341 | 86 | 182 | 73 | NA | 43 | 27 | 626.369821409 | 0.1395348907 | 0.29323861 |
81621D52-9EEB-46B3-B3AD-FCE458A29C0A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 691 | NA | NA | NA | 2.5 | N | 758 | 166 | 343 | 86 | 185 | 72 | NA | 41 | 25 | 643.8152237947 | 0.1162790731 | 0.2783053219 |
FA1C6040-1803-4093-8CAC-6061EE3F8CB8 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 691 | NA | NA | NA | 2.5 | N | 777 | 164 | 342 | 86 | 184 | 72 | NA | 46 | 27 | 659.2100747337 | 0.1162790731 | 0.2838477194 |
72DE2C1E-7FD0-4276-93F5-E3732FAB342A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 711 | NA | NA | NA | 3 | N | 720 | 169 | 335 | 84 | 176 | 75 | NA | 41 | 27 | 606.5666886435 | 0.1086956486 | 0.2841573358 |
7EDD412B-3638-4643-8489-28B02A34D485 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 711 | NA | NA | NA | 3 | N | 729 | 169 | 334 | 84 | 174 | 76 | NA | 40 | 26 | 626.1979439897 | 0.1086956486 | 0.2817217112 |
A52A6251-4000-48F3-B06A-223149C29161 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | 711 | NA | NA | NA | 3 | N | 722 | 169 | 336 | 85 | 175 | 76 | NA | 40 | 27 | 613.4707247038 | 0.1304347813 | 0.2845575213 |
2DF1A770-307D-4666-AA54-B245B82F30E6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1450 | NA | 1510 | NA | NA | NA | 6.5 | N | 696 | 162 | 354 | 89 | 182 | 83 | NA | 56 | 36 | 454.6641557056 | 0.1632653028 | 0.3538995087 |
78978C61-5441-451C-9745-652DF1C76C2E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1450 | NA | 1510 | NA | NA | NA | 6.5 | N | 705 | 165 | 356 | 90 | 182 | 84 | NA | 58 | 35 | 466.652446907 | 0.1599999964 | 0.3525213003 |
C3AE93AC-128B-44F5-8C02-466CD3E999AC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1450 | NA | 1510 | NA | NA | NA | 6.5 | N | 730 | 158 | 355 | 89 | 183 | 83 | NA | 58 | 33 | 468.956042434 | 0.1304347813 | 0.3592932224 |
626BC14E-D67D-4710-BEC4-E51E85B92DE8 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1370 | NA | 1520 | NA | NA | NA | 7 | N | 786 | 162 | 358 | 89 | 189 | 80 | NA | 59 | 35 | 445.4851797248 | 0.227272734 | 0.3611141443 |
BF2DB379-6A22-4243-BF84-487E94253A03 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1370 | NA | 1520 | NA | NA | NA | 7 | N | 784 | 161 | 359 | 89 | 186 | 84 | NA | 61 | 37 | 461.7332775501 | 0.1666666716 | 0.3795621395 |
FEA7513C-186B-4B19-8A47-6F897D47DCB0 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1370 | NA | 1520 | NA | NA | NA | 7 | N | 731 | 163 | 356 | 89 | 183 | 84 | NA | 61 | 34 | 453.5239892794 | 0.1777777821 | 0.3455033302 |
7F3C87DE-582D-427F-ACB3-047CF14C8DA6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1340 | NA | 1530 | NA | NA | NA | 7.5 | N | 655 | 167 | 350 | 91 | 170 | 89 | NA | 56 | 42 | 401.6008081426 | 0.0961538479 | 0.3610590994 |
C20554AB-3A1F-4229-B08C-FA6E4A1726A4 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1340 | NA | 1530 | NA | NA | NA | 7.5 | N | 690 | 165 | 350 | 90 | 176 | 84 | NA | 54 | 39 | 434.4088688488 | 0.1739130467 | 0.3484703004 |
E66CAFD2-A89C-435A-9D25-3BDC5D8B7871 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1340 | NA | 1530 | NA | NA | NA | 7.5 | N | 711 | 159 | 349 | 89 | 180 | 80 | NA | 59 | 34 | 439.2281022313 | 0.1702127606 | 0.3526514471 |
AB286607-1235-4E3E-9E13-2CD35A7ABF0E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1160 | NA | 1360 | NA | NA | NA | 8 | N | 720 | 168 | 355 | 89 | 181 | 85 | NA | 51 | 34 | 513.117988737 | 0.1224489808 | 0.3393943608 |
D44D8AD0-B95A-42AC-9988-401CF5E751B9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1160 | NA | 1360 | NA | NA | NA | 8 | N | 730 | 167 | 357 | 89 | 183 | 85 | NA | 55 | 32 | 502.3398980625 | 0.1836734712 | 0.355607301 |
F7167334-C305-470C-A1B8-5E25F7A2F13E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1160 | NA | 1360 | NA | NA | NA | 8 | N | 688 | 163 | 350 | 86 | 182 | 82 | NA | 54 | 31 | 516.4609324534 | 0.1666666716 | 0.3402992785 |
5B2A5782-95E7-478C-9B32-50E35A81AE62 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2160 | NA | 1890 | NA | NA | NA | 12 | N | 731 | 173 | 369 | 91 | 189 | 89 | NA | 57 | 45 | 434.4713707324 | 0.1800000072 | 0.3967326283 |
5CC7C71E-38D0-4FB9-B036-AAB8DB102573 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2160 | NA | 1890 | NA | NA | NA | 12 | N | 751 | 173 | 370 | 91 | 192 | 87 | NA | 61 | 41 | 426.3745115131 | 0.2399999946 | 0.4138057828 |
A30EE326-A96E-4249-90EC-369B728D83A3 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2160 | NA | 1890 | NA | NA | NA | 12 | N | 753 | 175 | 368 | 91 | 190 | 87 | NA | 63 | 40 | 409.6745873368 | 0.2127659619 | 0.410728395 |
0DCEA585-5C09-42FC-9FEC-E16E0C4C08A1 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1960 | NA | NA | NA | 12.5 | N | 720 | 174 | 364 | 90 | 184 | 90 | NA | 59 | 45 | 397.8006091003 | 0.2199999988 | 0.3985591829 |
605E3F4F-C9F7-4ED2-BC84-6699FA3E79E9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1960 | NA | NA | NA | 12.5 | N | 697 | 173 | 365 | 92 | 182 | 91 | NA | 59 | 48 | 384.2833692466 | 0.1836734712 | 0.3923817575 |
68E3ECF7-107F-478D-8813-FA4767966194 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1990 | NA | 1960 | NA | NA | NA | 12.5 | N | 753 | 171 | 366 | 91 | 183 | 92 | NA | 61 | 40 | 413.6456083653 | 0.1346153915 | 0.3804163039 |
7DE73757-6429-498A-8006-D0B2580DC501 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2000 | NA | 1830 | NA | NA | NA | 13 | N | 753 | 172 | 365 | 90 | 187 | 88 | NA | 59 | 37 | 431.813668224 | 0.2173912972 | 0.37682423 |
8E4EF60A-4AF2-446B-8CE4-3F4D91FB498C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2000 | NA | 1830 | NA | NA | NA | 13 | N | 756 | 169 | 362 | 88 | 187 | 87 | NA | 62 | 37 | 426.2132769197 | 0.2173912972 | 0.3880010545 |
F4E48CAB-31D9-4290-A070-607AA108BE60 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 2000 | NA | 1830 | NA | NA | NA | 13 | N | 750 | 174 | 358 | 90 | 185 | 83 | NA | 62 | 34 | 441.3650327835 | 0.1739130467 | 0.3735384345 |
01E3F10D-69D1-4C63-9577-48E1A64F2A24 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1740 | NA | 1880 | NA | NA | NA | 13.5 | N | 738 | 174 | 362 | 89 | 186 | 87 | NA | 62 | 36 | 429.4294484327 | 0.1632653028 | 0.3783617616 |
05E73548-37FE-4B46-9DC8-C65700FA6272 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1740 | NA | 1880 | NA | NA | NA | 13.5 | N | 707 | 179 | 365 | 91 | 188 | 86 | NA | 64 | 34 | 430.8402008428 | 0.1800000072 | 0.3883005977 |
22DFE8B7-84AE-4C89-9D3F-7F01DE802EF6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | 1740 | NA | 1880 | NA | NA | NA | 13.5 | N | 775 | 175 | 367 | 90 | 191 | 86 | NA | 62 | 35 | 451.154747336 | 0.195652172 | 0.3810958862 |
BC2D60FF-E7EC-46D2-8093-69FD75EF732B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 785 | 173 | 358 | 87 | 193 | 78 | NA | 48 | 30 | 575.248362835 | 0.1521739066 | 0.339846015 |
CFD1677D-D5F6-48F1-801E-2F69ACB2910D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 725 | 183 | 352 | 87 | 185 | 80 | NA | 49 | 32 | 549.1314687883 | 0.1666666716 | 0.3383905292 |
F53DE731-A6C4-4208-A79E-0A4BF4F991C5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-1-DOSING | Mexiletine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 752 | 180 | 358 | 88 | 190 | 80 | NA | 51 | 30 | 570.6034892326 | 0.1818181872 | 0.3278843164 |
623CB2EC-980B-46B4-8C84-C8D32E0CAB21 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 922 | 180 | 375 | 88 | 214 | 73 | NA | 46 | 28 | 682.3590900866 | 0.1190476194 | 0.3440852761 |
79CEB05E-544C-4FE1-B9C1-74FE7561E269 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 797 | 182 | 357 | 86 | 201 | 70 | NA | 43 | 24 | 645.3570378934 | 0.1190476194 | 0.3237838745 |
EBCD96AC-F6CD-4D3D-9B16-DF5CD8B06CCE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 839 | 176 | 365 | 88 | 206 | 71 | NA | 43 | 25 | 652.2688377265 | 0.146341458 | 0.3308590949 |
41011C53-9B56-4499-AAEE-F9FC41C3CEF6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 981 | NA | NA | NA | NA | 1.5 | N | 778 | 176 | 346 | 89 | 185 | 72 | NA | 43 | 26 | 598.7035295272 | 0.1190476194 | 0.2897154391 |
9B8E33A7-7E7E-4C1D-B372-48B35E835B31 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 981 | NA | NA | NA | NA | 1.5 | N | 778 | 179 | 346 | 88 | 186 | 72 | NA | 47 | 28 | 618.0046767612 | 0.113636367 | 0.3057854176 |
DF303C8C-1968-4224-BE6E-32682F752685 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 981 | NA | NA | NA | NA | 1.5 | N | 773 | 177 | 343 | 87 | 186 | 70 | NA | 47 | 29 | 612.1269741552 | 0.1707317084 | 0.2747829556 |
22512917-FF7E-4F78-B583-7858072EC712 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1210 | NA | NA | NA | NA | 2 | N | 764 | 172 | 342 | 88 | 181 | 73 | NA | 46 | 27 | 621.2792533459 | 0.1666666716 | 0.279183507 |
92AAA4EB-F713-41CA-AC87-E4A23F669597 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1210 | NA | NA | NA | NA | 2 | N | 781 | 166 | 345 | 88 | 186 | 71 | NA | 48 | 26 | 623.7635317939 | 0.1162790731 | 0.2974129617 |
ED9D2584-3E6E-46CE-A329-D3760E9F8927 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1210 | NA | NA | NA | NA | 2 | N | 763 | 165 | 342 | 86 | 186 | 70 | NA | 46 | 27 | 624.2270804617 | 0.1190476194 | 0.2942451239 |
4BE09DB1-AF77-48C8-9F90-D6BC5DCF75DB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2.5 | N | 817 | 175 | 346 | 89 | 186 | 71 | NA | 41 | 24 | 664.4233540531 | 0.1190476194 | 0.2991820574 |
AF82A7B7-CBB4-4B44-B0E4-3649A51BB90E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2.5 | N | 812 | 169 | 347 | 89 | 187 | 71 | NA | 45 | 27 | 649.6207364972 | 0.0930232555 | 0.2921867669 |
C9471C59-B2E5-44B6-8924-EF2FEAAB14FA | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 1070 | NA | NA | NA | NA | 2.5 | N | 765 | 177 | 346 | 88 | 186 | 72 | NA | 46 | 26 | 673.2696351639 | 0.1395348907 | 0.2929155827 |
4C61AC0C-0764-41AF-94B5-1783176546FE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 801 | 165 | 357 | 87 | 197 | 73 | NA | 42 | 25 | 676.2365879323 | 0.1190476194 | 0.2928936183 |
D5131873-D313-4783-8311-EFF6F7021AB7 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 931 | 170 | 360 | 87 | 200 | 73 | NA | 40 | 25 | 734.2702208074 | 0.095238097 | 0.3041918874 |
DC23BCC4-6A94-4A94-B03D-158772006AEC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | 814 | NA | NA | NA | NA | 3 | N | 861 | 169 | 354 | 86 | 197 | 71 | NA | 44 | 27 | 705.6214953609 | 0.0930232555 | 0.2823995948 |
23E963BF-DC45-4F6F-8885-10775BA2F398 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1440 | 1850 | NA | NA | NA | NA | 6.5 | N | 746 | 172 | 361 | 89 | 191 | 81 | NA | 61 | 34 | 482.4389013615 | 0.1555555612 | 0.3669960797 |
4D23B80F-2351-4CB9-8D76-C754059499D7 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1440 | 1850 | NA | NA | NA | NA | 6.5 | N | 779 | 168 | 362 | 87 | 193 | 82 | NA | 56 | 34 | 518.9083246149 | 0.1224489808 | 0.3679787517 |
ABC87493-1FD1-4D09-A2D3-40C3AB9B5C76 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1440 | 1850 | NA | NA | NA | NA | 6.5 | N | 788 | 176 | 365 | 89 | 193 | 83 | NA | 53 | 31 | 500.8348674886 | 0.1777777821 | 0.371984154 |
6D8CF474-FE90-49BC-ADCD-101F1768889C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1480 | 2070 | NA | NA | NA | NA | 7 | N | 707 | 171 | 365 | 89 | 184 | 92 | NA | 60 | 47 | 374.7646046772 | 0.1914893687 | 0.3901298046 |
90C5A112-F66F-4F63-8A4E-10CA1300C43C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1480 | 2070 | NA | NA | NA | NA | 7 | N | 815 | 175 | 376 | 90 | 196 | 90 | NA | 64 | 38 | 421.8770626891 | 0.2391304374 | 0.4080676138 |
BC81E2CD-35F0-4832-97C5-2FF259F66220 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1480 | 2070 | NA | NA | NA | NA | 7 | N | 792 | 174 | 379 | 92 | 197 | 90 | NA | 57 | 43 | 431.4625852096 | 0.2244897932 | 0.4102015495 |
0EB444EE-D126-4552-824B-4E40FCA9E45F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1450 | 2070 | NA | NA | NA | NA | 7.5 | N | 701 | 173 | 365 | 89 | 191 | 85 | NA | 62 | 36 | 410.9148965761 | 0.2127659619 | 0.401858747 |
30CCCF56-9E34-44C4-8AB8-CF41659006A9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1450 | 2070 | NA | NA | NA | NA | 7.5 | N | 754 | 174 | 364 | 89 | 192 | 83 | NA | 56 | 34 | 469.68518225 | 0.1739130467 | 0.3795932829 |
3BB31587-E8D6-461A-8E62-1B35CBABBDFA | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1450 | 2070 | NA | NA | NA | NA | 7.5 | N | 767 | 168 | 367 | 90 | 195 | 82 | NA | 57 | 33 | 470.6186153485 | 0.1666666716 | 0.3993497491 |
30199E63-398E-450B-953B-6F04664F41BC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1230 | 1450 | NA | NA | NA | NA | 8 | N | 771 | 177 | 368 | 89 | 198 | 81 | NA | 54 | 33 | 518.1194531985 | 0.1739130467 | 0.3778423071 |
6BDE6EF5-61D9-4CD1-A72D-D29D9B3ECF5A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1230 | 1450 | NA | NA | NA | NA | 8 | N | 781 | 173 | 367 | 87 | 199 | 81 | NA | 52 | 31 | 536.2172259398 | 0.1333333403 | 0.3649846315 |
AC8089D0-F59F-4A93-BCF6-55EC48964679 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1230 | 1450 | NA | NA | NA | NA | 8 | N | 767 | 169 | 366 | 89 | 196 | 81 | NA | 53 | 29 | 528.4852734053 | 0.1590909064 | 0.3781349957 |
A67CD38C-D839-44DE-8BF2-D7519726B4A7 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 963 | 1980 | NA | NA | NA | NA | 12 | N | 759 | 174 | 361 | 89 | 191 | 81 | NA | 52 | 32 | 548.4619304355 | 0.1224489808 | 0.3531601429 |
AD2BA2DB-2A41-4630-897C-F7AA3F68DEC9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 963 | 1980 | NA | NA | NA | NA | 12 | N | 787 | 172 | 366 | 91 | 195 | 80 | NA | 52 | 30 | 567.3916117118 | 0.1521739066 | 0.3383972347 |
E20A4E61-2C2B-4C61-91AE-2C08FB9F376F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 963 | 1980 | NA | NA | NA | NA | 12 | N | 759 | 175 | 360 | 89 | 191 | 80 | NA | 54 | 31 | 542.03350257 | 0.1428571492 | 0.3644301891 |
549F9948-974C-4905-9E2F-3283EB9FF13D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1060 | 2080 | NA | NA | NA | NA | 12.5 | N | 768 | 171 | 365 | 89 | 193 | 83 | NA | 54 | 31 | 510.1256992984 | 0.1428571492 | 0.3681442142 |
870F2907-6BB7-4BAB-A32C-02B721233054 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1060 | 2080 | NA | NA | NA | NA | 12.5 | N | 773 | 168 | 364 | 90 | 191 | 83 | NA | 56 | 31 | 494.0042407169 | 0.1276595742 | 0.3629550934 |
B452EFD2-72FB-4B3A-8480-9018FC4C03C2 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1060 | 2080 | NA | NA | NA | NA | 12.5 | N | 768 | 165 | 363 | 90 | 190 | 83 | NA | 57 | 31 | 501.5902807106 | 0.1632653028 | 0.3672406077 |
BAA6EBAA-636D-4672-A073-FFAB85865C90 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1210 | 2210 | NA | NA | NA | NA | 13 | N | 746 | 180 | 367 | 89 | 197 | 81 | NA | 56 | 31 | 495.6687530219 | 0.195652172 | 0.3815793693 |
BC338A7C-EEFD-4D4E-99A6-0A00438845E1 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1210 | 2210 | NA | NA | NA | NA | 13 | N | 823 | 175 | 369 | 90 | 196 | 83 | NA | 54 | 30 | 520.5498458568 | 0.1458333284 | 0.3643109202 |
EA5B7F04-4947-4781-9439-A5CE76F553BC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1210 | 2210 | NA | NA | NA | NA | 13 | N | 767 | 176 | 367 | 90 | 195 | 82 | NA | 54 | 30 | 520.3597607025 | 0.1521739066 | 0.3716688156 |
079D1B82-FBB0-4848-97D5-2EFE8E902C30 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1190 | 1570 | NA | NA | NA | NA | 13.5 | N | 855 | 173 | 375 | 90 | 205 | 80 | NA | 62 | 34 | 568.5114263469 | 0.1458333284 | 0.3883698583 |
6C1ED8E6-7C4B-45FC-A8E2-EE3D92813A4B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1190 | 1570 | NA | NA | NA | NA | 13.5 | N | 810 | 173 | 373 | 89 | 204 | 80 | NA | 55 | 32 | 569.5621563555 | 0.1739130467 | 0.3823352754 |
8FC2E273-6DFF-46E3-818F-30E5CC539D3A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | 1190 | 1570 | NA | NA | NA | NA | 13.5 | N | 824 | 172 | 373 | 88 | 202 | 83 | NA | 55 | 30 | 558.9084372327 | 0.1666666716 | 0.3878574371 |
64C6A48A-9F28-42D9-9C47-C689AA596EFB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 754 | 165 | 369 | 88 | 203 | 78 | NA | 49 | 28 | 595.932562904 | 0.1702127606 | 0.3508393466 |
CAEFBF6D-5850-48FA-B558-1C37EA05E5DC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 751 | 166 | 367 | 87 | 203 | 77 | NA | 49 | 28 | 610.4291113622 | 0.2325581461 | 0.3410395086 |
D05F58E1-BE70-49D8-B4B7-19C293095BFB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-2-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 720 | 177 | 368 | 86 | 204 | 78 | NA | 50 | 29 | 586.8469266918 | 0.2222222239 | 0.3521781564 |
0783D5DF-865C-45FA-90B0-9667EA9BF939 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 950 | 166 | 383 | 104 | 211 | 68 | NA | 43 | 27 | 585.182826217 | 0.097560972 | 0.3638006449 |
53733326-6DAC-45CD-AEE2-6E51BAC62F72 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 920 | 168 | 378 | 103 | 208 | 67 | NA | 45 | 25 | 581.4374226775 | 0.1219512224 | 0.3702618778 |
6AAD6EDA-DE4B-4920-9A1C-65EC0022B88D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | -0.5 | Y | 927 | 163 | 384 | 103 | 213 | 68 | NA | 44 | 26 | 588.8784925994 | 0.095238097 | 0.3684172034 |
512EFAC8-12E3-4AEB-8E81-96758416BD40 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4020 | 258 | NA | 1.5 | N | 687 | 176 | 338 | 88 | 181 | 69 | NA | 44 | 23 | 609.1306182126 | 0.146341458 | 0.29586941 |
5833C1DF-342C-4DAF-A3BB-9530279A7AC1 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4020 | 258 | NA | 1.5 | N | 670 | 177 | 338 | 88 | 182 | 68 | NA | 42 | 24 | 604.1335972704 | 0.1190476194 | 0.2878098786 |
92A9BDBD-D660-40DF-851D-539688736E2E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 4020 | 258 | NA | 1.5 | N | 687 | 179 | 339 | 85 | 186 | 68 | NA | 43 | 23 | 622.4055011728 | 0.146341458 | 0.3018795252 |
1270F246-C920-4E0F-966E-57C99771386B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7110 | 642 | NA | 2 | N | 710 | 176 | 348 | 87 | 190 | 71 | NA | 44 | 24 | 595.5693100506 | 0.195121944 | 0.3204996884 |
52A1FD2B-D6A7-450A-B77D-C405DACDC56F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7110 | 642 | NA | 2 | N | 764 | 173 | 351 | 89 | 190 | 72 | NA | 42 | 25 | 616.7728174044 | 0.1162790731 | 0.3344559371 |
DA36A798-9BC9-4F77-A2C3-EAF08BC201BE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7110 | 642 | NA | 2 | N | 698 | 177 | 343 | 88 | 186 | 69 | NA | 43 | 25 | 583.8948785402 | 0.1162790731 | 0.310289979 |
612D8C1C-A7EE-4777-B3A2-6A1D8AD27C96 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7060 | 902 | NA | 2.5 | N | 816 | 176 | 363 | 88 | 201 | 74 | NA | 45 | 25 | 639.5777076472 | 0.1190476194 | 0.322268039 |
69F3351A-2368-463A-A83D-0A2D188089E8 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7060 | 902 | NA | 2.5 | N | 764 | 174 | 361 | 88 | 202 | 71 | NA | 41 | 25 | 644.9096800889 | 0.1395348907 | 0.3074824214 |
E2EBED00-9026-432C-81A4-9D9A68FD979F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 7060 | 902 | NA | 2.5 | N | 756 | 175 | 361 | 88 | 202 | 71 | NA | 44 | 25 | 622.8307245232 | 0.1666666716 | 0.311962992 |
00AC8579-8E89-4E86-99B1-35BA27FE05E5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6090 | 921 | NA | 3 | N | 775 | 170 | 362 | 87 | 199 | 76 | NA | 44 | 25 | 614.9634319641 | 0.1428571492 | 0.332894206 |
11868B7E-444A-4712-95DB-A57EFB4C061D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6090 | 921 | NA | 3 | N | 765 | 170 | 360 | 88 | 198 | 74 | NA | 45 | 25 | 593.9293624031 | 0.1666666716 | 0.3438452184 |
DDB9B7B5-1897-4899-917C-C8C86B321299 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 6090 | 921 | NA | 3 | N | 782 | 175 | 362 | 89 | 199 | 74 | NA | 45 | 25 | 606.6938830856 | 0.1627907008 | 0.3301798105 |
A3F60D41-8454-435F-8130-65205FE493A6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9330 | 1370 | NA | 6.5 | N | 727 | 168 | 360 | 89 | 195 | 76 | NA | 48 | 29 | 560.0525028231 | 0.1590909064 | 0.3547486663 |
CB43DBD0-3505-438B-BA11-63B83FB4D578 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9330 | 1370 | NA | 6.5 | N | 751 | 165 | 362 | 89 | 197 | 76 | NA | 48 | 28 | 556.5384294952 | 0.1363636404 | 0.3714434803 |
EB6377CC-46DB-46FB-BD97-1FD1DBC82D12 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9330 | 1370 | NA | 6.5 | N | 726 | 168 | 361 | 88 | 197 | 76 | NA | 47 | 28 | 565.9881404298 | 0.1162790731 | 0.3613414466 |
29907A43-C646-4430-88AA-BEB4FC3DF472 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12300 | 1800 | NA | 7 | N | 755 | 171 | 365 | 90 | 199 | 76 | NA | 52 | 28 | 519.1296417995 | 0.1521739066 | 0.4015966356 |
BEAB729F-9009-4CC2-A0D1-1462B67A2BC9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12300 | 1800 | NA | 7 | N | 710 | 168 | 358 | 88 | 194 | 76 | NA | 55 | 28 | 499.8930267349 | 0.2093023211 | 0.4025833607 |
DFC23C49-5F59-4AB2-869C-E313BECCC716 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12300 | 1800 | NA | 7 | N | 732 | 167 | 361 | 89 | 197 | 75 | NA | 53 | 29 | 468.6801482412 | 0.1590909064 | 0.4133648574 |
26148692-D180-481B-8BD3-4D01D46526CB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 11600 | 2060 | NA | 7.5 | N | 722 | 173 | 362 | 88 | 197 | 77 | NA | 63 | 32 | 503.7566153435 | 0.1555555612 | 0.3984617889 |
A5549D2F-6D88-4E77-8056-E299C0CEF807 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 11600 | 2060 | NA | 7.5 | N | 715 | 175 | 365 | 90 | 196 | 79 | NA | 52 | 28 | 523.2295605956 | 0.125 | 0.3990753293 |
D453A884-76BF-46DE-B9F0-A4DB9F4733A4 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 11600 | 2060 | NA | 7.5 | N | 692 | 177 | 361 | 88 | 195 | 78 | NA | 51 | 30 | 518.2718325679 | 0.1489361674 | 0.3900809586 |
254AEA24-EFB6-4180-AF31-7E5D521FB298 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10500 | 2120 | NA | 8 | N | 765 | 168 | 366 | 89 | 197 | 80 | NA | 52 | 30 | 549.8217344204 | 0.1458333284 | 0.3900877535 |
3E1D2C68-286A-491D-8EC6-0403E1228747 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10500 | 2120 | NA | 8 | N | 761 | 173 | 369 | 87 | 200 | 82 | NA | 51 | 30 | 573.009712864 | 0.1458333284 | 0.3931233883 |
9F1DCEC6-8239-4EEB-B432-7B6ED4093C25 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10500 | 2120 | NA | 8 | N | 688 | 174 | 367 | 88 | 197 | 82 | NA | 53 | 30 | 535.6874349318 | 0.1632653028 | 0.3952842355 |
5F243418-8CF8-428A-9164-627063783724 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12900 | 1950 | 69.4 | 12 | N | 644 | 184 | 351 | 87 | 179 | 85 | NA | 50 | 31 | 518.5438426361 | 0.1224489808 | 0.3425525427 |
7F707612-B369-4682-92C7-5DB8C5058F48 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12900 | 1950 | 69.4 | 12 | N | 663 | 185 | 352 | 88 | 183 | 81 | NA | 50 | 31 | 542.1689088976 | 0.125 | 0.3434924483 |
E7E8A577-331A-464C-891D-7DBEA632A521 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 12900 | 1950 | 69.4 | 12 | N | 634 | 184 | 353 | 88 | 180 | 85 | NA | 50 | 32 | 517.560618047 | 0.1458333284 | 0.3425186276 |
2512AF8F-51C0-45E5-AE49-1F858FE19D1F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10600 | 2160 | 86.9 | 12.5 | N | 721 | 189 | 365 | 87 | 194 | 84 | NA | 57 | 35 | 489.1713290631 | 0.1836734712 | 0.406573683 |
50A3D81F-881D-4EA8-B1AC-73CEC0BCB890 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10600 | 2160 | 86.9 | 12.5 | N | 689 | 192 | 361 | 87 | 192 | 82 | NA | 54 | 32 | 517.6123070783 | 0.1599999964 | 0.3981091678 |
BBEDA737-C8FB-4E7D-B136-85C3897B5589 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10600 | 2160 | 86.9 | 12.5 | N | 663 | 206 | 362 | 86 | 191 | 85 | NA | 62 | 32 | 498.1560402936 | 0.2340425551 | 0.3997763097 |
9B74FAF8-2CDB-43DF-BCEC-FB528A2973FB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10400 | 2160 | 84.2 | 13 | N | 638 | 198 | 362 | 87 | 189 | 86 | NA | 77 | 41 | 466.060879161 | 0.1923076957 | 0.4190524817 |
DA8F8ECF-B7C8-4C98-BF83-2208CDC03EF9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10400 | 2160 | 84.2 | 13 | N | 614 | 206 | 362 | 86 | 189 | 87 | NA | 87 | 42 | 421.7448186556 | 0.3000000119 | 0.4369740784 |
E10C7502-3B97-4FD8-945F-CF9E841D283E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 10400 | 2160 | 84.2 | 13 | N | 702 | 189 | 363 | 89 | 190 | 84 | NA | 63 | 31 | 485.7957592028 | 0.1764705926 | 0.4087702632 |
02768974-6D23-46C7-B088-2F725FBE8562 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9390 | 2100 | 57.9 | 13.5 | N | 766 | 179 | 372 | 88 | 198 | 86 | NA | 69 | 37 | 505.7684208744 | 0.1599999964 | 0.4254010916 |
741E48DE-020E-45E2-9F17-E62BAFE1E720 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9390 | 2100 | 57.9 | 13.5 | N | 747 | 184 | 374 | 87 | 201 | 86 | NA | 58 | 33 | 521.1389136884 | 0.1875 | 0.412987113 |
D2968355-9204-41B7-A833-FB66C5937673 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | 9390 | 2100 | 57.9 | 13.5 | N | 730 | 179 | 369 | 85 | 197 | 87 | NA | 64 | 39 | 536.1035617843 | 0.1458333284 | 0.4147166312 |
609342DC-34BE-4461-BA4D-97366F663871 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 783 | 166 | 386 | 87 | 215 | 84 | NA | 54 | 30 | 574.9854423456 | 0.2391304374 | 0.4039463997 |
6AEA5A98-7C68-4A27-A374-C03F9DA53404 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 826 | 169 | 383 | 86 | 214 | 83 | NA | 50 | 31 | 579.3607606579 | 0.1875 | 0.3975191712 |
7BC4BAF6-62AE-481A-92E0-3EBF2C24188D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-3-DOSING | Moxifloxacin + Diltiazem | NA | NA | NA | NA | NA | NA | 24 | N | 846 | 168 | 383 | 87 | 214 | 82 | NA | 52 | 30 | 587.5121592277 | 0.1875 | 0.3891629577 |
1322E132-78A1-4FD9-8B2D-C8CCF767CC61 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 780 | 182 | 364 | 89 | 203 | 72 | NA | 42 | 25 | 708.9255290401 | 0.113636367 | 0.3401714563 |
20C24FBB-B3B2-4402-A658-B39F23F9DF32 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 894 | 185 | 374 | 89 | 211 | 74 | NA | 43 | 25 | 695.223625478 | 0.1304347813 | 0.3509018719 |
DAA53825-2DD9-4FC7-9973-0E5B8BB6E482 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 905 | 186 | 374 | 90 | 210 | 74 | NA | 42 | 26 | 722.7266607806 | 0.1395348907 | 0.3515282869 |
1F3EBFF6-6387-4B9D-A94E-3FF20150B21A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 737 | 181 | 341 | 89 | 181 | 71 | NA | 42 | 24 | 617.4755753118 | 0.1162790731 | 0.3061494529 |
69999E69-C7B1-40BC-A0A7-BAD4D67C8E64 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 790 | 176 | 348 | 90 | 188 | 70 | NA | 40 | 23 | 670.5884989321 | 0.1428571492 | 0.291085273 |
79D4B4B8-1B97-4A88-B9AC-DC55B46E430B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 798 | 174 | 344 | 89 | 184 | 71 | NA | 41 | 25 | 650.918966684 | 0.095238097 | 0.2813258171 |
04E53AB7-F59B-4618-969F-13EF151A282F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 779 | 180 | 343 | 87 | 185 | 71 | NA | 45 | 27 | 658.366251998 | 0.1219512224 | 0.2951185405 |
731A2745-9FAF-4CAD-A4ED-DA20DDF00C6B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 963 | 178 | 360 | 86 | 201 | 73 | NA | 45 | 28 | 727.9943869561 | 0.0909090936 | 0.3338925838 |
7DC71068-75F7-4384-B2C9-CC5808BBEED7 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 677 | 181 | 343 | 87 | 186 | 70 | NA | 42 | 23 | 596.1230456673 | 0.174999997 | 0.3146229386 |
D17EC37A-4683-40D8-84F4-4E4D2C783817 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 820 | 180 | 342 | 86 | 186 | 70 | NA | 45 | 26 | 665.1546332557 | 0.125 | 0.2864804268 |
E053BEE1-1EA0-4AA2-89E9-5105D928D7B9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 813 | 180 | 346 | 87 | 187 | 72 | NA | 38 | 25 | 704.556956522 | 0.1190476194 | 0.2891078889 |
FF7ABEAA-AD3A-4B7D-95DF-04052B5631BC | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 797 | 178 | 346 | 88 | 187 | 71 | NA | 42 | 26 | 708.8586968489 | 0.095238097 | 0.3004329503 |
86229339-767E-4DD4-9871-124D4D9FB71E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 781 | 179 | 350 | 89 | 187 | 74 | NA | 46 | 29 | 658.1979338358 | 0.1304347813 | 0.3086229861 |
93D45914-C99A-47FB-BD55-17FD1DD97C4E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 895 | 175 | 364 | 88 | 201 | 75 | NA | 42 | 25 | 707.3095680288 | 0.1162790731 | 0.3209347427 |
BDAA2C2E-96C1-49C3-8DB9-3DD8B42A735B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 764 | 178 | 353 | 88 | 192 | 73 | NA | 42 | 25 | 651.4997144226 | 0.1428571492 | 0.3276396692 |
5C07DE0D-F7A0-4CE9-9FA3-DC513E1E1B35 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 817 | 162 | 349 | 90 | 188 | 71 | NA | 43 | 25 | 608.4469022452 | 0.1428571492 | 0.3211643398 |
DB735500-DF9F-468C-835D-AC13F2BCDE1C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 809 | 169 | 349 | 89 | 190 | 70 | NA | 40 | 25 | 631.5948842995 | 0.150000006 | 0.3221476972 |
FA68A936-A1F2-418B-B16C-3BEB805DB174 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 834 | 166 | 349 | 87 | 190 | 72 | NA | 42 | 25 | 615.8607354943 | 0.1162790731 | 0.3232454658 |
2D8F19EF-22BC-4C48-BA1D-AF84B83BD577 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 926 | 172 | 361 | 89 | 199 | 73 | NA | 42 | 27 | 701.9123033584 | 0.1395348907 | 0.3570542336 |
805741EB-0E83-4389-B33E-E46073FB5D28 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 820 | 165 | 357 | 88 | 198 | 71 | NA | 48 | 28 | 656.6456569633 | 0.1428571492 | 0.3424078822 |
B1213603-3DE7-4F5C-B6B4-AC86DB637031 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 848 | 163 | 360 | 88 | 200 | 72 | NA | 43 | 25 | 672.4288067622 | 0.1190476194 | 0.337138474 |
0C80EA02-02CF-4550-9925-95A016F65F29 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 838 | 169 | 353 | 85 | 196 | 72 | NA | 41 | 25 | 693.1856997971 | 0.1190476194 | 0.3271717727 |
6C13F12C-4C60-4473-B63D-8D6462817B48 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 827 | 169 | 354 | 86 | 197 | 71 | NA | 45 | 27 | 701.5610786949 | 0.095238097 | 0.3282580972 |
C2A5652D-03D5-4F73-B0C7-DEE2EC3A9582 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 825 | 169 | 350 | 87 | 192 | 71 | NA | 42 | 24 | 671.6416426944 | 0.0930232555 | 0.3326559365 |
2B4E3DDE-64F9-4716-B4AD-BF5C2BEB4BB6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 828 | 173 | 360 | 87 | 200 | 73 | NA | 49 | 29 | 652.5649380403 | 0.1190476194 | 0.350189656 |
C2185386-BBA6-486A-9151-4B8CCB357499 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 843 | 169 | 362 | 88 | 202 | 72 | NA | 45 | 26 | 666.6426896633 | 0.1627907008 | 0.3445224464 |
CB78EE8F-C053-4C0A-9217-75AF4E711B8A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 740 | 178 | 361 | 86 | 201 | 74 | NA | 44 | 26 | 641.4944893349 | 0.1590909064 | 0.3597441018 |
6E5CF798-896E-4D72-9A46-FF5B91F310B0 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 820 | 177 | 354 | 87 | 193 | 74 | NA | 43 | 24 | 695.6897432817 | 0.1190476194 | 0.3083669841 |
8CC7467F-89EF-41A2-A9FF-E68257214410 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 821 | 175 | 358 | 90 | 194 | 74 | NA | 42 | 26 | 675.9866622082 | 0.1162790731 | 0.2917815745 |
EE0982B7-031B-4952-B66C-32EC8AC4E3D1 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 827 | 173 | 357 | 89 | 195 | 73 | NA | 41 | 25 | 696.5148890913 | 0.097560972 | 0.2924575508 |
1E10D6C0-0FA9-4D91-8074-4CD43507E3EF | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 902 | 176 | 373 | 88 | 210 | 75 | NA | 44 | 27 | 699.8884436372 | 0.1627907008 | 0.326113224 |
39FECAC3-640A-418C-BCB5-6DDB39B211B9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 884 | 177 | 372 | 89 | 208 | 75 | NA | 43 | 26 | 709.8683669422 | 0.113636367 | 0.3336740732 |
B4601213-18F2-4581-ADC2-2B1561186D47 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 901 | 176 | 370 | 89 | 205 | 76 | NA | 43 | 28 | 694.0798974913 | 0.1395348907 | 0.3367034793 |
3A26CFF6-2999-4E37-8C38-B306170B6641 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 852 | 172 | 365 | 89 | 203 | 73 | NA | 42 | 26 | 679.9804271342 | 0.1428571492 | 0.3341845572 |
652BF38B-3B39-490F-B19A-251EA1EADDA9 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 900 | 172 | 367 | 89 | 203 | 75 | NA | 44 | 26 | 675.2733509509 | 0.1304347813 | 0.3430483341 |
E16424BE-CA0E-4373-891B-BE95BAF2B93D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 846 | 169 | 367 | 90 | 203 | 74 | NA | 44 | 25 | 659.1225138328 | 0.1162790731 | 0.3420596719 |
78CF8010-BA41-4B5A-BAB9-2F1DA2BE5909 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 953 | 182 | 365 | 90 | 201 | 74 | NA | 44 | 26 | 682.4552257186 | 0.1086956486 | 0.3207535148 |
82A3A384-7D39-4936-BB4A-639AC3C65031 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 803 | 177 | 365 | 91 | 199 | 75 | NA | 44 | 27 | 640.3238798473 | 0.125 | 0.3610120714 |
AAD709BF-DD7B-4A31-A736-6F33F05886E5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 873 | 169 | 363 | 90 | 200 | 73 | NA | 45 | 27 | 617.2663314415 | 0.1395348907 | 0.3254809976 |
9BA5E798-9ADD-4921-AC74-4AC4D71D8BCE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 800 | 182 | 355 | 87 | 196 | 72 | NA | 46 | 26 | 707.6551890055 | 0.1428571492 | 0.3244338036 |
D11820F8-EAB5-43CD-87F7-75B7A16BA9C5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 814 | 183 | 357 | 88 | 197 | 72 | NA | 48 | 26 | 681.5015229962 | 0.1627907008 | 0.3371565342 |
E02BD6B0-EF99-41F2-9147-573A96F75712 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-4-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 24 | N | 738 | 179 | 353 | 87 | 194 | 72 | NA | 46 | 26 | 661.1774208371 | 0.1590909064 | 0.3167693019 |
25338715-28F1-42EF-BFF6-A6000E0A45CE | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 929 | 184 | 387 | 91 | 219 | 77 | NA | 46 | 27 | 664.970853235 | 0.1521739066 | 0.3850560784 |
814C8ED2-1D86-4390-96CD-04224F7A12D2 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 907 | 185 | 382 | 90 | 216 | 76 | NA | 44 | 27 | 666.0761674097 | 0.1739130467 | 0.3809591234 |
A8050141-DE3D-498D-90FB-04BCE36FB424 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 902 | 186 | 384 | 89 | 219 | 76 | NA | 44 | 27 | 672.8611016663 | 0.1627907008 | 0.3656657338 |
2A6D280B-8F7F-4055-A151-B70E3DBCE6FB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 725 | 187 | 353 | 89 | 193 | 71 | NA | 43 | 24 | 631.0723616581 | 0.1666666716 | 0.314065069 |
3D5A4DF3-A308-4813-B11B-9097CC29653F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 777 | 189 | 355 | 89 | 194 | 72 | NA | 42 | 26 | 643.5617441407 | 0.1521739066 | 0.327931881 |
C65F461E-F79C-4F79-B4EA-FCCA4242820E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 1.5 | N | 846 | 190 | 357 | 88 | 197 | 72 | NA | 42 | 25 | 666.7164199329 | 0.1627907008 | 0.3278119564 |
3935A21A-0190-4390-AC57-A8CB16974026 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 885 | 176 | 363 | 87 | 204 | 72 | NA | 46 | 28 | 667.3911807382 | 0.1428571492 | 0.3432518244 |
80F98A11-60FE-41BB-84BF-82040D92B241 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 778 | 188 | 361 | 89 | 199 | 73 | NA | 47 | 29 | 643.2577788022 | 0.1333333403 | 0.3403884172 |
82CC7E5E-5A69-4107-99D3-AF2B8B2F31EA | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2 | N | 840 | 193 | 361 | 88 | 200 | 73 | NA | 48 | 27 | 665.2107452001 | 0.1428571492 | 0.3298697174 |
442A3738-5074-4EA6-A754-714E8BEC4C6D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 922 | 176 | 372 | 88 | 211 | 73 | NA | 47 | 29 | 697.8850558681 | 0.1162790731 | 0.3475066125 |
8747E2E7-19C0-4E7D-9FED-F063AC4414F5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 815 | 190 | 359 | 88 | 199 | 72 | NA | 41 | 25 | 667.0028194669 | 0.1333333403 | 0.3223610222 |
C453375B-D606-4D57-BE2C-73544744DC74 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 2.5 | N | 859 | 175 | 368 | 88 | 207 | 73 | NA | 43 | 25 | 688.7865569595 | 0.1162790731 | 0.3255072534 |
54CF559E-A03C-4371-9167-3A7133F0095C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 828 | 189 | 360 | 87 | 197 | 76 | NA | 42 | 25 | 676.2840001599 | 0.1304347813 | 0.3256503642 |
78F4C91C-C91D-438B-A88A-1B24F0B79CA3 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 706 | 183 | 355 | 89 | 191 | 75 | NA | 44 | 26 | 591.6785823082 | 0.1590909064 | 0.3296965659 |
99FA31E9-4C4C-468B-9DFA-80038965CC0A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 3 | N | 942 | 184 | 362 | 87 | 200 | 75 | NA | 42 | 27 | 703.376699506 | 0.1162790731 | 0.3137630522 |
6087D66C-6598-4D1A-9202-FC191104F21E | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 276 | NA | NA | NA | NA | NA | 6.5 | N | 776 | 182 | 357 | 91 | 190 | 76 | NA | 47 | 31 | 527.8303027877 | 0.113636367 | 0.3738880455 |
ADDB8CA2-84DE-4663-B2D9-033993BED334 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 276 | NA | NA | NA | NA | NA | 6.5 | N | 832 | 179 | 360 | 91 | 194 | 75 | NA | 46 | 27 | 568.5816220352 | 0.1190476194 | 0.3745712936 |
EFEB8134-D6E9-4691-AA11-48F277D4F914 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 276 | NA | NA | NA | NA | NA | 6.5 | N | 805 | 185 | 356 | 90 | 190 | 76 | NA | 48 | 28 | 552.3753225754 | 0.1363636404 | 0.3723347187 |
2FABE25B-FE8E-4CD5-ABD8-ED03D4E8E4C7 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 502 | NA | NA | NA | NA | NA | 7 | N | 811 | 183 | 368 | 90 | 201 | 77 | NA | 51 | 31 | 546.844193895 | 0.1489361674 | 0.3969393969 |
98E03004-2143-4E90-A2F1-2DB5B4F94815 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 502 | NA | NA | NA | NA | NA | 7 | N | 880 | 176 | 373 | 90 | 207 | 76 | NA | 50 | 30 | 551.0163126334 | 0.1363636404 | 0.3932667971 |
B41C7E65-601A-4626-8707-C070C2016EDF | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 502 | NA | NA | NA | NA | NA | 7 | N | 958 | 173 | 380 | 90 | 213 | 77 | NA | 48 | 30 | 558.43108622 | 0.1489361674 | 0.4089237154 |
4CD03FE5-B5A8-4C37-B134-1F0C05B4E4C5 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 589 | NA | NA | NA | NA | NA | 7.5 | N | 852 | 188 | 373 | 89 | 206 | 78 | NA | 47 | 30 | 590.838183445 | 0.1363636404 | 0.3851950467 |
533353ED-C3FC-4D6B-8C8F-077AAABAE39A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 589 | NA | NA | NA | NA | NA | 7.5 | N | 852 | 182 | 367 | 87 | 206 | 74 | NA | 46 | 28 | 592.0440845398 | 0.1276595742 | 0.3795706928 |
BAC5250B-D07A-4062-9A2D-7C04FCB32B2F | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 589 | NA | NA | NA | NA | NA | 7.5 | N | 811 | 188 | 369 | 88 | 205 | 76 | NA | 47 | 29 | 586.8871922113 | 0.1590909064 | 0.377689153 |
184A118A-E6FE-4DA1-801E-AA46A0D1DF63 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 743 | NA | NA | NA | NA | NA | 8 | N | 721 | 185 | 368 | 89 | 199 | 80 | NA | 53 | 30 | 545.1406619158 | 0.2083333284 | 0.396930486 |
A9BE2E6E-433D-4353-892D-76F24115070B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 743 | NA | NA | NA | NA | NA | 8 | N | 815 | 174 | 377 | 87 | 211 | 79 | NA | 50 | 30 | 588.8312955848 | 0.1818181872 | 0.3850415647 |
BA6098DE-FA24-4DA3-AE74-9CAC3B521E1C | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 743 | NA | NA | NA | NA | NA | 8 | N | 822 | 184 | 377 | 90 | 209 | 78 | NA | 50 | 28 | 618.1251793368 | 0.1875 | 0.4002584815 |
409578ED-00D6-4AFF-ABD7-20F8D406FFC6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1830 | NA | NA | NA | NA | NA | 12 | N | 851 | 174 | 407 | 93 | 227 | 87 | NA | 67 | 37 | 491.3322966394 | 0.3829787374 | 0.4610273838 |
5C1DC225-9EE6-431A-AAFC-C1EC4DBE67CB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1830 | NA | NA | NA | NA | NA | 12 | N | 820 | 176 | 403 | 93 | 217 | 93 | NA | 65 | 42 | 477.2921071663 | 0.3137255013 | 0.4531187415 |
61F184FE-DB09-41E4-80F3-5030FA8B5041 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1830 | NA | NA | NA | NA | NA | 12 | N | 843 | 176 | 407 | 92 | 226 | 89 | NA | 66 | 36 | 499.2647034605 | 0.3829787374 | 0.4608500302 |
34553089-6A06-498C-9BFC-268A6ADBE0DB | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1870 | NA | NA | NA | NA | NA | 12.5 | N | 934 | 185 | 401 | 91 | 224 | 86 | NA | 64 | 37 | 554.9499888598 | 0.2599999905 | 0.4528194368 |
3F02AF5D-6D90-4F19-B279-BA902A6C5655 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1870 | NA | NA | NA | NA | NA | 12.5 | N | 750 | 185 | 402 | 90 | 228 | 84 | NA | 77 | 33 | 452.2274051091 | 0.6086956263 | 0.4776668847 |
794D245B-8003-4AF7-B36D-EFBCF33AE26B | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1870 | NA | NA | NA | NA | NA | 12.5 | N | 785 | 182 | 407 | 91 | 230 | 86 | NA | 75 | 35 | 484.4165030329 | 0.4893617034 | 0.469424516 |
02417A9D-DA30-4DF5-B681-638AC6D50790 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 2030 | NA | NA | NA | NA | NA | 13 | N | 791 | 183 | 402 | 89 | 226 | 87 | NA | 77 | 35 | 474.3596490469 | 0.4199999869 | 0.4781192243 |
44DCC04E-DEC1-4A1F-AFDB-DF924FADC358 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 2030 | NA | NA | NA | NA | NA | 13 | N | 833 | 185 | 404 | 90 | 228 | 86 | NA | 72 | 36 | 506.7991656111 | 0.4117647111 | 0.4693810046 |
E8BC5639-35A0-403D-8D0A-C4A234143F86 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 2030 | NA | NA | NA | NA | NA | 13 | N | 819 | 187 | 402 | 90 | 226 | 86 | NA | 69 | 36 | 512.1871856048 | 0.3541666567 | 0.4630546868 |
8EAC834C-CFB1-427F-8677-539C1652864D | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1800 | NA | NA | NA | NA | NA | 13.5 | N | 852 | 186 | 395 | 90 | 216 | 89 | NA | 68 | 37 | 512.0296157782 | 0.2800000012 | 0.448182106 |
C04D082D-04B1-477C-A154-12BB840F4531 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1800 | NA | NA | NA | NA | NA | 13.5 | N | 852 | 177 | 398 | 90 | 222 | 86 | NA | 65 | 36 | 520.092266464 | 0.2941176593 | 0.4596452415 |
EF6093B9-8644-4971-A741-0F6A54DE4EE6 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | 1800 | NA | NA | NA | NA | NA | 13.5 | N | 891 | 186 | 396 | 90 | 218 | 88 | NA | 64 | 37 | 540.2378154852 | 0.2352941185 | 0.4523801804 |
0E7BEA0E-BF8F-48D4-9C1D-DB711CB183E2 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 756 | 171 | 360 | 87 | 196 | 77 | NA | 56 | 31 | 542.870209198 | 0.2093023211 | 0.3625422418 |
6DAA4B98-1D28-469C-BCF2-2D713103965A | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 734 | 167 | 358 | 88 | 195 | 75 | NA | 50 | 28 | 526.7913371468 | 0.2142857164 | 0.3609088063 |
71B0423C-ECEE-4F78-9E6B-017E0C3D92A2 | 2002 | F | 30 | 165 | 74.2 | 107.67 | 72.67 | WHITE | NOT HISPANIC OR LATINO | C-B-D-E-A | PERIOD-5-DOSING | Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 733 | 176 | 359 | 87 | 197 | 75 | NA | 51 | 27 | 518.9318900003 | 0.2045454532 | 0.3663135469 |
1A5BD89F-35F3-4CE2-9CAF-83E54287EA35 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 956 | 124 | 418 | 91 | 243 | 84 | NA | 43 | 30 | 536.9547034015 | 0.1458333284 | 0.4403907359 |
38967015-4C37-439C-A8A8-9CD14C4C0FFA | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 945 | 123 | 417 | 91 | 243 | 83 | NA | 43 | 29 | 523.3966297371 | 0.1304347813 | 0.4494988024 |
3C1189A8-4962-46AB-BE8A-A80700A3B834 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | -0.5 | Y | 955 | 126 | 413 | 88 | 243 | 82 | NA | 42 | 29 | 525.980633746 | 0.1555555612 | 0.4289313257 |
A947185D-6DE1-4099-9C76-C76050295146 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1370 | NA | NA | NA | NA | 1.5 | N | 961 | 121 | 384 | 90 | 216 | 78 | NA | 39 | 27 | 577.1951079903 | 0.1041666642 | 0.3961594403 |
B191F6FE-CA57-4511-8DE5-D3E534061841 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1370 | NA | NA | NA | NA | 1.5 | N | 957 | 124 | 386 | 90 | 216 | 80 | NA | 40 | 25 | 562.468801323 | 0.1276595742 | 0.389423728 |
CAA1B59F-BFA6-4744-A905-011BF6A79672 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1370 | NA | NA | NA | NA | 1.5 | N | 945 | 120 | 383 | 87 | 217 | 79 | NA | 41 | 27 | 553.0626845096 | 0.1590909064 | 0.3950861096 |
296F15EF-11DB-4389-A5CF-7BBCFB31DC51 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1480 | NA | NA | NA | NA | 2 | N | 948 | 122 | 389 | 91 | 218 | 80 | NA | 40 | 26 | 578.7091873003 | 0.1489361674 | 0.3987456858 |
A5FB23C2-A215-4829-A813-AA43913ADDA3 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1480 | NA | NA | NA | NA | 2 | N | 961 | 129 | 387 | 90 | 216 | 81 | NA | 41 | 26 | 565.0635361555 | 0.1777777821 | 0.4034622908 |
EB2F7719-5FF3-4ED5-BC9B-7B835A6D4F8D | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1480 | NA | NA | NA | NA | 2 | N | 975 | 116 | 387 | 86 | 222 | 79 | NA | 40 | 27 | 588.2445063101 | 0.1777777821 | 0.3906058073 |
13C50D7E-E2B4-4BF8-AC19-C34F78EAE69E | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1290 | NA | NA | NA | NA | 2.5 | N | 987 | 134 | 392 | 87 | 225 | 80 | NA | 40 | 27 | 587.1610154377 | 0.1458333284 | 0.4208992124 |
8FD58CDA-8286-421B-8062-A45437ED7EBE | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1290 | NA | NA | NA | NA | 2.5 | N | 1005 | 132 | 396 | 89 | 225 | 82 | NA | 41 | 26 | 594.5659287993 | 0.1276595742 | 0.4192812741 |
EFD27D42-597B-4F00-9948-27DE02BC9A40 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1290 | NA | NA | NA | NA | 2.5 | N | 1008 | 131 | 397 | 91 | 225 | 81 | NA | 41 | 26 | 586.7991118064 | 0.1489361674 | 0.4300764799 |
7A22BD71-ABC0-4DAC-BB85-65123E1C03FC | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1090 | NA | NA | NA | NA | 3 | N | 924 | 107 | 380 | 85 | 216 | 79 | NA | 43 | 27 | 564.5398043269 | 0.1777777821 | 0.4178496599 |
C493586C-D768-435A-9C59-9632FCAA9BBF | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1090 | NA | NA | NA | NA | 3 | N | 927 | 108 | 377 | 85 | 214 | 78 | NA | 42 | 27 | 544.5840483766 | 0.1914893687 | 0.401743114 |
E2768286-FA75-40DC-94B0-67CEFD3272BA | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | 1090 | NA | NA | NA | NA | 3 | N | 964 | 107 | 382 | 87 | 217 | 78 | NA | 42 | 26 | 587.9320650008 | 0.1666666716 | 0.413300842 |
3030271B-2071-4840-881A-2AA16EB57CCD | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 124 | 2270 | NA | NA | NA | NA | 6.5 | N | 861 | 132 | 386 | 90 | 214 | 82 | NA | 45 | 29 | 434.0159418587 | 0.1304347813 | 0.3779783249 |
3BE54C73-3E8B-46B5-ADCD-30D9C40D71E1 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 124 | 2270 | NA | NA | NA | NA | 6.5 | N | 891 | 133 | 387 | 88 | 217 | 82 | NA | 45 | 30 | 439.5943472954 | 0.1875 | 0.4227744639 |
4E098B39-C072-46B8-B934-869753F0FB51 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 124 | 2270 | NA | NA | NA | NA | 6.5 | N | 917 | 132 | 390 | 90 | 216 | 84 | NA | 45 | 31 | 454.3573217483 | 0.1739130467 | 0.414431572 |
19AEFCC7-A6F2-4363-9663-CADA4D13B71C | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 316 | 2330 | NA | NA | NA | NA | 7 | N | 804 | 129 | 376 | 87 | 209 | 80 | NA | 47 | 31 | 400.7313429887 | 0.2666666806 | 0.4079479277 |
A889A458-0A07-4D04-B6D6-209629E4BF76 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 316 | 2330 | NA | NA | NA | NA | 7 | N | 889 | 130 | 389 | 87 | 215 | 87 | NA | 50 | 30 | 419.6833403053 | 0.1666666716 | 0.4074693024 |
EBEFE29E-8C9F-4501-A59B-B768942EC9A9 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 316 | 2330 | NA | NA | NA | NA | 7 | N | 904 | 116 | 384 | 84 | 218 | 82 | NA | 47 | 32 | 436.2477341011 | 0.1739130467 | 0.4103599489 |
04BF89AD-F818-4CFB-9B76-C094D3153FD5 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 411 | 2320 | NA | NA | NA | NA | 7.5 | N | 865 | 111 | 385 | 85 | 221 | 79 | NA | 46 | 31 | 437.2697640646 | 0.1632653028 | 0.4117658138 |
3114E7B5-D39B-4A55-BAEC-4380F5862BFB | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 411 | 2320 | NA | NA | NA | NA | 7.5 | N | 900 | 111 | 383 | 82 | 221 | 80 | NA | 47 | 29 | 462.4152541384 | 0.1836734712 | 0.4256955385 |
3DCDFC87-683E-4BFE-B7FC-8553AEE778F7 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 411 | 2320 | NA | NA | NA | NA | 7.5 | N | 884 | 118 | 385 | 84 | 223 | 78 | NA | 49 | 29 | 441.13547366 | 0.1914893687 | 0.4259948134 |
4BDF8C09-C599-424D-86F8-AA67718F54ED | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 640 | 1570 | NA | NA | NA | NA | 8 | N | 921 | 111 | 396 | 84 | 231 | 81 | NA | 47 | 30 | 500.4099803174 | 0.2340425551 | 0.442640692 |
6D638DBD-14DC-4271-9BB2-9C4EFD1852B1 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 640 | 1570 | NA | NA | NA | NA | 8 | N | 865 | 128 | 401 | 89 | 229 | 83 | NA | 47 | 31 | 468.1530075135 | 0.2244897932 | 0.4429514408 |
A38719AC-7714-465A-A222-1BA174ED7E39 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 640 | 1570 | NA | NA | NA | NA | 8 | N | 887 | 114 | 396 | 85 | 228 | 83 | NA | 49 | 29 | 484.0363398475 | 0.1914893687 | 0.4339401424 |
01FED0BA-CE10-4E74-A8A6-F049B6F5FD30 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2310 | 2330 | NA | NA | NA | NA | 12 | N | 985 | 118 | 429 | 90 | 248 | 91 | NA | 59 | 31 | 457.0266038108 | 0.2549019754 | 0.4935346842 |
D12972E5-1BEA-44E7-A6B7-B340D5EB4C7E | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2310 | 2330 | NA | NA | NA | NA | 12 | N | 951 | 121 | 427 | 88 | 248 | 91 | NA | 57 | 32 | 442.2364110711 | 0.2941176593 | 0.5001070499 |
E1B00A83-B4D0-4817-95D9-84E2F05C5A2A | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2310 | 2330 | NA | NA | NA | NA | 12 | N | 989 | 121 | 431 | 88 | 251 | 92 | NA | 55 | 32 | 457.8868647764 | 0.3000000119 | 0.5012897849 |
2AAA28EA-ADA9-4393-88BC-05F40FDE2A61 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2630 | 2840 | NA | NA | NA | NA | 12.5 | N | 947 | 131 | 428 | 88 | 250 | 90 | NA | 61 | 33 | 418.4094226523 | 0.387755096 | 0.5129588246 |
59564EBC-E928-4211-B361-2FC62520E14C | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2630 | 2840 | NA | NA | NA | NA | 12.5 | N | 900 | 132 | 428 | 88 | 249 | 91 | NA | 61 | 33 | 411.1674587037 | 0.3137255013 | 0.49173522 |
AACADD98-D215-4C8B-BFAA-ACA07816D5AE | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2630 | 2840 | NA | NA | NA | NA | 12.5 | N | 895 | 130 | 426 | 89 | 246 | 91 | NA | 59 | 33 | 415.1068154694 | 0.4042553306 | 0.4948382974 |
0D638130-EF85-41D1-B15E-C739CF15C16F | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2650 | 2600 | NA | NA | NA | NA | 13 | N | 884 | 130 | 427 | 85 | 250 | 92 | NA | 65 | 34 | 376.9873854576 | 0.3125 | 0.4918597341 |
15A25A69-A624-4E08-832C-2A58FB2995A6 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2650 | 2600 | NA | NA | NA | NA | 13 | N | 952 | 127 | 435 | 85 | 257 | 93 | NA | 65 | 37 | 390.5277423169 | 0.4042553306 | 0.5101635456 |
E5366491-F7C8-44B4-8A09-E0C7998FDBB3 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2650 | 2600 | NA | NA | NA | NA | 13 | N | 957 | 110 | 431 | 83 | 257 | 91 | NA | 63 | 36 | 410.0986827417 | 0.3076923192 | 0.5142915249 |
038C126B-62C9-419E-A442-DBE4855885ED | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2250 | 1940 | NA | NA | NA | NA | 13.5 | N | 964 | 122 | 439 | 87 | 260 | 92 | NA | 58 | 34 | 488.9619762955 | 0.3404255211 | 0.5232061148 |
787D6BDD-DC79-4E86-AF83-7E574CF5E4D0 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2250 | 1940 | NA | NA | NA | NA | 13.5 | N | 951 | 121 | 437 | 89 | 254 | 94 | NA | 56 | 34 | 505.8280976722 | 0.4166666567 | 0.5113410354 |
F20124DE-E997-4027-B483-6867D627E0EC | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | 2250 | 1940 | NA | NA | NA | NA | 13.5 | N | 942 | 134 | 440 | 90 | 255 | 95 | NA | 58 | 34 | 474.2558975829 | 0.3404255211 | 0.5101441741 |
78C991C0-AEAA-434A-999C-6D097BE9C1E2 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 946 | 118 | 427 | 89 | 254 | 84 | NA | 48 | 30 | 539.6980297584 | 0.2291666716 | 0.4871551394 |
8EFCE9EB-1C29-4F1E-9564-46FAD6C62067 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 908 | 131 | 430 | 90 | 254 | 86 | NA | 46 | 31 | 535.0530922315 | 0.2083333284 | 0.4767615199 |
94E9735F-5AAC-42CC-A4D0-8DFA7E58AF90 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-1-DOSING | Lidocaine + Dofetilide | NA | NA | NA | NA | NA | NA | 24 | N | 904 | 117 | 416 | 90 | 244 | 82 | NA | 45 | 29 | 546.9611770817 | 0.1836734712 | 0.466979593 |
0E96FA1B-6363-41B8-A052-30B9C89D0D85 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 970 | 117 | 415 | 93 | 240 | 82 | NA | 42 | 29 | 553.5703827021 | 0.1489361674 | 0.4282510579 |
6F5CDA68-F666-447D-AFE9-CF8134CA88ED | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 958 | 125 | 410 | 92 | 238 | 80 | NA | 40 | 28 | 577.8025774915 | 0.1458333284 | 0.4336865842 |
8DDF7B5A-A334-45BF-BEED-015EDDF45B5F | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | -0.5 | Y | 946 | 123 | 411 | 89 | 244 | 78 | NA | 42 | 28 | 577.3118031108 | 0.1521739066 | 0.4306131303 |
4BAC93F1-9B8B-4168-893C-324C80967F4C | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 902 | 119 | 384 | 90 | 215 | 79 | NA | 39 | 28 | 531.433238032 | 0.1304347813 | 0.3783386648 |
B58107F4-95FA-4098-9630-0C317FD9070E | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 934 | 123 | 390 | 91 | 220 | 79 | NA | 40 | 29 | 538.0538979696 | 0.1739130467 | 0.3968063891 |
E6D647B2-DD87-40DA-9618-D51EEABEEC00 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 1.5 | N | 936 | 125 | 387 | 89 | 219 | 79 | NA | 40 | 28 | 545.9443747755 | 0.1555555612 | 0.3871501982 |
5D51160F-A41F-4F1B-8D62-87E34710DD75 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 918 | 130 | 385 | 87 | 221 | 77 | NA | 41 | 26 | 515.8302476865 | 0.125 | 0.3940170407 |
8C844E70-501C-413E-8EFE-8FB128D7D358 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 955 | 131 | 391 | 87 | 224 | 80 | NA | 41 | 27 | 538.1121771479 | 0.1521739066 | 0.4087424576 |
CE366698-8121-466E-8609-C3A6728B4BF9 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2 | N | 961 | 120 | 390 | 89 | 223 | 78 | NA | 40 | 27 | 536.7592849041 | 0.1458333284 | 0.3950012922 |
CC4B013E-5D3B-401D-8900-FFCB3D842849 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 939 | 129 | 390 | 90 | 222 | 78 | NA | 39 | 27 | 555.1809135764 | 0.1063829809 | 0.3794105649 |
EECC42D6-EB1F-4A1F-9509-98C0C5692DD5 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 961 | 124 | 392 | 89 | 226 | 77 | NA | 39 | 27 | 553.0181754511 | 0.1304347813 | 0.3807241619 |
FD0A8EB7-E752-4D4B-8814-AF865AA9794A | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 2.5 | N | 961 | 130 | 390 | 89 | 223 | 78 | NA | 38 | 26 | 547.7137141165 | 0.1333333403 | 0.3982279599 |
26FDF9FC-2DE6-49DB-BCE9-867F298BD960 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 1022 | 118 | 400 | 91 | 231 | 78 | NA | 40 | 28 | 616.0576065086 | 0.1199999973 | 0.4132846296 |
4B58666E-4C96-4010-8ECA-E1E1C6084E64 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 994 | 128 | 404 | 91 | 234 | 79 | NA | 41 | 28 | 597.0168071147 | 0.1276595742 | 0.4151992202 |
6B6F55C6-60EC-448B-BD0B-87069FF8B399 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 3 | N | 1010 | 124 | 399 | 91 | 231 | 77 | NA | 41 | 26 | 607.5024470583 | 0.125 | 0.4060582817 |
2402A348-1DBA-46C0-952F-349138D82F5B | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 897 | 126 | 392 | 89 | 221 | 82 | NA | 46 | 29 | 420.2761231875 | 0.1063829809 | 0.413900286 |
EEDB3C6F-E4B0-4413-A428-2A5A3C7C7FD4 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 867 | 113 | 390 | 87 | 224 | 79 | NA | 45 | 31 | 423.9982979028 | 0.1555555612 | 0.3941446245 |
F876E35F-1B53-43DB-AEFC-C8640099EF5D | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 6.5 | N | 900 | 126 | 396 | 89 | 225 | 82 | NA | 44 | 31 | 438.5607910032 | 0.1521739066 | 0.4013412893 |
0D88066B-3603-43C7-80F4-F53A1EE945BD | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 940 | 113 | 395 | 89 | 225 | 81 | NA | 45 | 30 | 467.8182324259 | 0.1632653028 | 0.4133206904 |
1CC5D543-4A64-4F4C-8269-B9F561602009 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 898 | 130 | 399 | 89 | 225 | 85 | NA | 43 | 32 | 464.2141948622 | 0.1458333284 | 0.3971950114 |
1F563505-2977-41AC-856C-0043EB6CFD28 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7 | N | 901 | 127 | 393 | 88 | 225 | 80 | NA | 46 | 31 | 440.947296954 | 0.200000003 | 0.40742746 |
179E5F90-5CE1-453A-90D8-92982CB85036 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 875 | 113 | 391 | 87 | 226 | 78 | NA | 42 | 30 | 458.7824669652 | 0.1777777821 | 0.4029905498 |
4ACF9DD4-04BD-4A53-8B79-AB73645C80B7 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 882 | 118 | 393 | 87 | 226 | 80 | NA | 43 | 31 | 460.9783747428 | 0.1521739066 | 0.3851764202 |
B4FC6D9E-FE52-457B-9E08-C2954C660395 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 7.5 | N | 883 | 130 | 398 | 88 | 227 | 83 | NA | 44 | 31 | 450.4648876558 | 0.1666666716 | 0.4016617835 |
7D20650D-36FE-4AC8-98CA-4A72B244EB9F | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 932 | 111 | 396 | 86 | 231 | 79 | NA | 41 | 30 | 542.5409049855 | 0.1276595742 | 0.4090636373 |
9A6F1B89-6C36-4AA3-9DEC-5095D3971A3B | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 927 | 127 | 397 | 87 | 229 | 81 | NA | 41 | 30 | 531.3782303879 | 0.1224489808 | 0.4117964208 |
D440411D-97EB-4A53-8618-CE5909EFAE65 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 8 | N | 940 | 119 | 394 | 87 | 227 | 80 | NA | 40 | 29 | 539.3156639541 | 0.1041666642 | 0.3902267218 |
0E15D8C0-9033-4608-9608-7728640B3390 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 930 | 117 | 391 | 87 | 223 | 81 | NA | 42 | 29 | 500.6503667094 | 0.1555555612 | 0.4077860415 |
379E333C-7D66-4D6E-B2FF-F7CD244DDAD2 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 906 | 117 | 394 | 91 | 222 | 81 | NA | 44 | 29 | 481.0702884204 | 0.1458333284 | 0.3993084729 |
BBF1E79E-78F8-4F5A-A43A-428B6231E6B9 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12 | N | 894 | 121 | 388 | 89 | 217 | 82 | NA | 41 | 28 | 475.1129449757 | 0.1086956486 | 0.3999244869 |
01C344CA-AD7B-419F-BBD5-9AAEAF36B95B | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 997 | 116 | 398 | 89 | 230 | 79 | NA | 44 | 29 | 481.7407479159 | 0.1199999973 | 0.4148855805 |
7A54B399-C049-485B-9C51-E37C915653B8 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 951 | 116 | 393 | 88 | 226 | 79 | NA | 41 | 29 | 498.4509522693 | 0.1276595742 | 0.401575923 |
9A1AA6AD-E963-47A7-973B-B8C9369CA4A3 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 12.5 | N | 954 | 116 | 394 | 88 | 227 | 79 | NA | 42 | 30 | 488.2234650628 | 0.1224489808 | 0.4045287967 |
294F7A38-ADC1-4F5F-9E97-30EBF62AD920 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 933 | 121 | 396 | 88 | 229 | 79 | NA | 43 | 28 | 510.6700399018 | 0.1666666716 | 0.407541573 |
50FA2C71-3244-4879-9997-64886C11DE40 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 949 | 113 | 399 | 89 | 229 | 81 | NA | 42 | 30 | 506.6298134075 | 0.1458333284 | 0.4219912589 |
C176B654-B6B5-4926-BE03-76A5FC783706 | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13 | N | 900 | 125 | 396 | 87 | 228 | 81 | NA | 43 | 28 | 492.6604930577 | 0.1458333284 | 0.427642107 |
612F2D0A-E16F-4D0D-9100-004D437F52CB | 2003 | F | 23 | 172 | 69.3 | 111 | 58.33 | WHITE | NOT HISPANIC OR LATINO | B-E-C-A-D | PERIOD-2-DOSING | Placebo | NA | NA | NA | NA | NA | NA | 13.5 | N | 948 | 118 | 399 | 88 | 230 | 81 | NA | 42 | 29 | 520.5152710891 | 0.1555555612 | 0.4108429849 |